

STN Columbus

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JUL 28 CA/CAPplus patent coverage enhanced
NEWS 3 JUL 28 EPFULL enhanced with additional legal status
information from the epoline Register
NEWS 4 JUL 28 IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 5 JUL 28 STN Viewer performance improved
NEWS 6 AUG 01 INPADOCDB and INPAFAMDB coverage enhanced
NEWS 7 AUG 13 CA/CAPplus enhanced with printed Chemical Abstracts
page images from 1967-1998
NEWS 8 AUG 15 CAOLD to be discontinued on December 31, 2008
NEWS 9 AUG 15 CAPplus currency for Korean patents enhanced
NEWS 10 AUG 27 CAS definition of basic patents expanded to ensure
comprehensive access to substance and sequence
information
NEWS 11 SEP 18 Support for STN Express, Versions 6.01 and earlier,
to be discontinued
NEWS 12 SEP 25 CA/CAPplus current-awareness alert options enhanced
to accommodate supplemental CAS indexing of
exemplified prophetic substances
NEWS 13 SEP 26 WPIDS, WPINDEX, and WPIX coverage of Chinese and
and Korean patents enhanced
NEWS 14 SEP 29 IFICLS enhanced with new super search field
NEWS 15 SEP 29 EMBASE and EMBAL enhanced with new search and
display fields
NEWS 16 SEP 30 CAS patent coverage enhanced to include exemplified
prophetic substances identified in new Japanese-
language patents
NEWS 17 OCT 07 EPFULL enhanced with full implementation of EPC2000
NEWS 18 OCT 07 Multiple databases enhanced for more flexible patent
number searching
NEWS 19 OCT 22 Current-awareness alert (SDI) setup and editing
enhanced
NEWS 20 OCT 22 WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
Applications
NEWS 21 OCT 24 CHEMLIST enhanced with intermediate list of
pre-registered REACH substances

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 20:29:26 ON 28 OCT 2008

=> file medline

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'MEDLINE' ENTERED AT 20:30:04 ON 28 OCT 2008

FILE LAST UPDATED: 28 Oct 2008 (20081028/UP). FILE COVERS 1949 TO DATE.

MEDLINE has been updated with the National Library of Medicine's revised 2008 MeSH terms. See HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

See HELP RANGE before carrying out any RANGE search.

MEDLINE Accession Numbers (ANs) for records from 1950-1977 have been converted from 8 to 10 digits. Searches using an 8 or 10 digit AN will retrieve the same record. The 10-digit ANs can be expanded, searched, and displayed in all records from 1949 to the present.

=> s (disaccharide or trehalose or cellobiose)

5011 DISACCHARIDE

3872 TREHALOSE

2092 CELLOBIOSE

L1 10476 (DISACCHARIDE OR TREHALOSE OR CELLOBIOSE)

=> s (diacid or di-acid or succinic acid or adipic acid or glutaric acid or pimelic acid or s

411 DIACID

1647170 DI

1581780 ACID

15 DI-ACID

(DI(W)ACID)

6096 SUCCINIC

1581780 ACID

2877 SUCCINIC ACID

(SUCCINIC(W)ACID)

1285 ADIPIC

1581780 ACID

470 ADIPIC ACID

(ADIPIC(W)ACID)

1030 GLUTARIC

1581780 ACID

604 GLUTARIC ACID

(GLUTARIC(W)ACID)

486 PIMELIC

1581780 ACID

104 PIMELIC ACID

(PIMELIC(W)ACID)

135 SUBERIC

1581780 ACID

82 SUBERIC ACID

(SUBERIC(W)ACID)

339 AZELAIC

1581780 ACID

319 AZELAIC ACID

(AZELAIC(W)ACID)

266 SEBACIC

1581780 ACID

196 SEBACIC ACID

(SEBACIC(W)ACID)

L2 4865 (DIACID OR DI-ACID OR SUCCINIC ACID OR ADIPIC ACID OR GLUTARIC ACID OR PIMELIC ACID OR SUBERIC ACID OR AZELAIC ACID OR SEBACIC ACID)

=> s l1 and l2

L3 23 L1 AND L2

=> d 1-23

L3 ANSWER 1 OF 23 MEDLINE on STN

Full Text

AN 2008428224 IN-PROCESS

DN PubMed ID: 18597311

TI Simultaneous saccharification and fermentation of cellulose to lactic acid.

AU Abe S; Takagi M

CS Bioscience Research Laboratories, Nippon Mining Co., Ltd., Niizominami

3-17-35, Toda, Saitama, Japan.
SO Biotechnology and bioengineering, (1991 Jan 5) Vol. 37, No. 1, pp. 93-6.
Journal code: 7502021. ISSN: 0006-3592.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS NONMEDLINE; IN-DATA-REVIEW; IN-PROCESS; NONINDEXED
ED Entered STN: 4 Jul 2008
Last Updated on STN: 4 Jul 2008

L3 ANSWER 2 OF 23 MEDLINE on STN
Full Text
AN 2007763457 MEDLINE
DN PubMed ID: 18156785
TI Determination of differences in the nonvolatile metabolites of
pine-mushrooms (*Tricholoma matsutake* Sing.) according to different parts
and heating times using 1H NMR and principal component analysis.
AU Cho In Hee; Kim Young-Suk; Lee Ki-Won; Choi Hyung-Kyoon
CS Department of Food Science and Technology, Ewha Womans University, Seoul,
Korea.
SO Journal of microbiology and biotechnology, (2007 Oct) Vol. 17, No. 10, pp.
1682-7.
Journal code: 9431852. ISSN: 1017-7825.
CY Korea (South)
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200802
ED Entered STN: 27 Dec 2007
Last Updated on STN: 29 Feb 2008
Entered Medline: 28 Feb 2008

L3 ANSWER 3 OF 23 MEDLINE on STN
Full Text
AN 2007074184 MEDLINE
DN PubMed ID: 17029671
TI Metabolomic discrimination of different grades of pine-mushroom
(*Tricholoma matsutake* Sing.) using 1H NMR spectrometry and multivariate
data analysis.
AU Cho In Hee; Kim Young-Suk; Choi Hyung-Kyoon
CS Department of Food Science and Technology, Ewha Womans University, Seoul
120-750, Republic of Korea.
SO Journal of pharmaceutical and biomedical analysis, (2007 Feb 19) Vol. 43,
No. 3, pp. 900-4. Electronic Publication: 2006-10-06.
Journal code: 8309336. ISSN: 0731-7085.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200704
ED Entered STN: 6 Feb 2007
Last Updated on STN: 14 Apr 2007
Entered Medline: 13 Apr 2007

L3 ANSWER 4 OF 23 MEDLINE on STN
Full Text
AN 2006215698 MEDLINE
DN PubMed ID: 16622056
TI Succinate-mediated catabolite repression control on the production of
glycine betaine catabolic enzymes in *Pseudomonas aeruginosa* PAO1 under low
and elevated salinities.
AU Diab Fares; Bernard Theophile; Bazire Alexis; Haras Dominique; Blanco
Carlos; Jebbar Mohamed
CS Departement Osmoregulation chez les Bacteries, UMR-CNRS 6026, Universite
de Rennes 1, Campus de Beaulieu, Av. du General Leclerc, 35042 Rennes,
France.
SO Microbiology (Reading, England), (2006 May) Vol. 152, No. Pt 5, pp.
1395-406.
Journal code: 9430468. ISSN: 1350-0872.
CY England: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200609
ED Entered STN: 20 Apr 2006
Last Updated on STN: 22 Sep 2006
Entered Medline: 21 Sep 2006

L3 ANSWER 5 OF 23 MEDLINE on STN
Full Text
AN 2004478975 MEDLINE
DN PubMed ID: 15340778
TI Alkaliflexus imshenetskii gen. nov. sp. nov., a new alkaliphilic gliding carbohydrate-fermenting bacterium with propionate formation from a soda lake.
AU Zhilina Tatyana N; Appel Ramona; Probian Christina; Brossa Enrique Llobet; Harder Jens; Widdel Friedrich; Zavarzin Georgii A
CS Institute of Microbiology of the Russian Academy of Sciences, Prospect 60-let Oktyabrya 7/2, 117312 Moscow, Russia.
SO Archives of microbiology, (2004 Oct) Vol. 182, No. 2-3, pp. 244-53.
Electronic Publication: 2004-08-31.
Journal code: 0410427. ISSN: 0302-8933.
CY Germany: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
OS GENBANK-AJ784993
EM 200504
ED Entered STN: 28 Sep 2004
Last Updated on STN: 19 Apr 2005
Entered Medline: 18 Apr 2005

L3 ANSWER 6 OF 23 MEDLINE on STN
Full Text
AN 2004151146 MEDLINE
DN PubMed ID: 15045103
TI Efficient electrophilic catalysis of 1,5-anhydrocellobiitol hydrolysis by Al(III); implications for the conservation of "rosin-alum" sized paper.
AU Baty John; Sinnott Michael L
CS Department of Textiles and Paper, UMIST, Manchester, UK..
J.Baty@postgrad.umist.ac.uk
SO Chemical communications (Cambridge, England), (2004 Apr 7) No. 7, pp. 866-7. Electronic Publication: 2004-02-27.
Journal code: 9610838. ISSN: 1359-7345.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200504
ED Entered STN: 27 Mar 2004
Last Updated on STN: 19 Dec 2004
Entered Medline: 19 Apr 2005

L3 ANSWER 7 OF 23 MEDLINE on STN
Full Text
AN 2003461379 MEDLINE
DN PubMed ID: 14523120
TI Degradation of alkanes and highly chlorinated benzenes, and production of biosurfactants, by a psychrophilic Rhodococcus sp. and genetic characterization of its chlorobenzene dioxygenase.
AU Rapp Peter; Gabriel-Jurgens Lotte H E
CS GBF-National Research Centre for Biotechnology, Division of Microbiology, Mascheroderweg 1, D-38124 Braunschweig, Germany.. pra@gbf.de
SO Microbiology (Reading, England), (2003 Oct) Vol. 149, No. Pt 10, pp. 2879-90.
Journal code: 9430468. ISSN: 1350-0872.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals

EM 200312
ED Entered STN: 3 Oct 2003
Last Updated on STN: 18 Dec 2003
Entered Medline: 11 Dec 2003

L3 ANSWER 8 OF 23 MEDLINE on STN

Full Text

AN 2001363623 MEDLINE
DN PubMed ID: 11386868
TI Characterization of dicarboxylic acids for cellulose hydrolysis.
AU Mosier N S; Sarikaya A; Ladisch C M; Ladisch M R
CS Department of Agricultural and Biological Engineering, Laboratory of Renewable Resources Engineering, Purdue University, West Lafayette, Indiana 47907, USA.
SO Biotechnology progress, (2001 May-Jun) Vol. 17, No. 3, pp. 474-80.
Journal code: 8506292. ISSN: 8756-7938.
CY United States
DT (COMPARATIVE STUDY)
(EVALUATION STUDIES)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
LA English
FS Priority Journals
EM 200110
ED Entered STN: 22 Oct 2001
Last Updated on STN: 22 Oct 2001
Entered Medline: 18 Oct 2001

L3 ANSWER 9 OF 23 MEDLINE on STN

Full Text

AN 2000014290 MEDLINE
DN PubMed ID: 10548254
TI Preparation of novel conjugates involving immunomodulating peptidoglycan monomer.
AU Tomasic J; Spoljar B; Ljevakovic D; Glaudemans C P
CS Institute of Immunology, Inc., Zagreb, Croatia.
SO Preparative biochemistry & biotechnology, (1999 Nov) Vol. 29, No. 4, pp. 385-401.
Journal code: 9607037. ISSN: 1082-6068.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 199911
ED Entered STN: 11 Jan 2000
Last Updated on STN: 11 Jan 2000
Entered Medline: 16 Nov 1999

L3 ANSWER 10 OF 23 MEDLINE on STN

Full Text

AN 1999449962 MEDLINE
DN PubMed ID: 10520259
TI A novel trisaccharide glycolipid biosurfactant containing **trehalose** bears ester-linked hexanoate, succinate, and acyloxyacyl moieties: NMR and MS characterization of the underivatized structure.
AU Esch S W; Morton M D; Williams T D; Buller C S
CS Higuchi Biosciences Center, University of Kansas, Lawrence 66047, USA.
NC S10 RR0 6294-01 (United States NCRR)
SO Carbohydrate research, (1999 Jun 30) Vol. 319, No. 1-4, pp. 112-23.
Journal code: 0043535. ISSN: 0008-6215.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LA English
FS Priority Journals
EM 199912
ED Entered STN: 13 Jan 2000
Last Updated on STN: 13 Jan 2000
Entered Medline: 17 Dec 1999

L3 ANSWER 11 OF 23 MEDLINE on STN

Full Text

AN 1999288190 MEDLINE
DN PubMed ID: 10334839
TI Characterization of metabolites in intact *Streptomyces citricolor* culture supernatants using high-resolution nuclear magnetic resonance and directly coupled high-pressure liquid chromatography-nuclear magnetic resonance spectroscopy.
AU Abel C B; Lindon J C; Noble D; Rudd B A; Sidebottom P J; Nicholson J K
CS Biological Chemistry, Division of Biomedical Sciences, Imperial College of Science, Technology, and Medicine, Sir Alexander Fleming Building, South Kensington, London, SW7 2AZ, United Kingdom.
SO Analytical biochemistry, (1999 Jun 1) Vol. 270, No. 2, pp. 220-30.
Journal code: 0370535. ISSN: 0003-2697.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 199907
ED Entered STN: 15 Jul 1999
Last Updated on STN: 15 Jul 1999
Entered Medline: 6 Jul 1999

L3 ANSWER 12 OF 23 MEDLINE on STN

Full Text

AN 1999287840 MEDLINE
DN PubMed ID: 10348870
TI Carbon-13 nuclear magnetic resonance study of metabolism of propionate by *Escherichia coli*.
AU London R E; Allen D L; Gabel S A; DeRose E F
CS Laboratory of Structural Biology, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA..
london@niehs.nih.gov
SO Journal of bacteriology, (1999 Jun) Vol. 181, No. 11, pp. 3562-70.
Journal code: 2985120R. ISSN: 0021-9193.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199906
ED Entered STN: 14 Jul 1999
Last Updated on STN: 14 Jul 1999
Entered Medline: 28 Jun 1999

L3 ANSWER 13 OF 23 MEDLINE on STN

Full Text

AN 1998401484 MEDLINE
DN PubMed ID: 9731297
TI Burkholderia graminis sp. nov., a rhizospheric Burkholderia species, and reassessment of [*Pseudomonas*] phenazinium, [*Pseudomonas*] pyrrocinia and [*Pseudomonas*] glathei as Burkholderia.
AU Viallard V; Poirier I; Cournoyer B; Haurat J; Wiebkin S; Ophel-Keller K; Balandreau J
CS Laboratoire d'Ecologie Microbienne du Sol, UMR5557 CNRS-Universite, Lyon I, Villeurbanne, France.. lemsl@biomserv.univ-lyon1.fr
SO International journal of systematic bacteriology, (1998 Apr) Vol. 48 Pt 2, pp. 549-63.
Journal code: 0042143. ISSN: 0020-7713.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
OS GENBANK-U96927; GENBANK-U96928; GENBANK-U96929; GENBANK-U96930; GENBANK-U96931; GENBANK-U96932; GENBANK-U96933; GENBANK-U96934; GENBANK-U96935; GENBANK-U96936; GENBANK-U96937; GENBANK-U96938; GENBANK-U96939; GENBANK-U96940; GENBANK-U96941
EM 199810
ED Entered STN: 21 Oct 1998
Last Updated on STN: 21 Oct 1998
Entered Medline: 14 Oct 1998

L3 ANSWER 14 OF 23 MEDLINE on STN
Full Text
AN 1998234010 MEDLINE
DN PubMed ID: 9573066
TI Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis.
AU Gu X X; Chen J; Barenkamp S J; Robbins J B; Tsai C M; Lim D J; Battey J
CS Laboratory of Immunology, National Institute on Deafness and Other Communication Disorders, Rockville, Maryland 20850, USA..
xgu@pop.nidcd.nih.gov
SO Infection and immunity, (1998 May) Vol. 66, No. 5, pp. 1891-7.
Journal code: 0246127. ISSN: 0019-9567.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199805
ED Entered STN: 20 May 1998
Last Updated on STN: 20 May 1998
Entered Medline: 14 May 1998

L3 ANSWER 15 OF 23 MEDLINE on STN
Full Text
AN 1998041309 MEDLINE
DN PubMed ID: 9373931
TI Production of succinate from glucose, **cellobiose**, and various cellulosic materials by the ruminal anaerobic bacteria Fibrobacter succinogenes and Ruminococcus flavefaciens.
AU Gokarn R R; Eiteman M A; Martin S A; Eriksson K E
CS Department of Biological and Agricultural Engineering, Driftmier Engineering Center, University of Georgia, Athens 30602, USA.
SO Applied biochemistry and biotechnology, (1997 Oct-Nov) Vol. 68, No. 1-2, pp. 69-80.
Journal code: 8208561. ISSN: 0273-2289.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 199802
ED Entered STN: 17 Feb 1998
Last Updated on STN: 17 Feb 1998
Entered Medline: 3 Feb 1998

L3 ANSWER 16 OF 23 MEDLINE on STN
Full Text
AN 1997443327 MEDLINE
DN PubMed ID: 9298188
TI Formation of formate and hydrogen, and flux of reducing equivalents and carbon in Ruminococcus flavefaciens FD-1.
AU Shi Y; Weimer P J; Ralph J
CS Department of Bacteriology, University of Wisconsin-Madison 53706, USA.
SO Antonie van Leeuwenhoek, (1997 Aug) Vol. 72, No. 2, pp. 101-9.
Journal code: 0372625. ISSN: 0003-6072.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
LA English
FS Priority Journals
EM 199711
ED Entered STN: 24 Dec 1997
Last Updated on STN: 24 Dec 1997
Entered Medline: 17 Nov 1997

L3 ANSWER 17 OF 23 MEDLINE on STN
Full Text
AN 1997231268 MEDLINE
DN PubMed ID: 9076663
TI Differentiation of human promyelocytic leukemia cell line HL60 by microbial extracellular glycolipids.
AU Isoda H; Shinmoto H; Kitamoto D; Matsumura M; Nakahara T

CS Institute of Applied Biochemistry, University of Tsukuba, Ibaraki, Japan.
SO Lipids, (1997 Mar) Vol. 32, No. 3, pp. 263-71.
Journal code: 0060450. ISSN: 0024-4201.
CY United States
DT (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199706
ED Entered STN: 20 Jun 1997
Last Updated on STN: 6 Feb 1998
Entered Medline: 12 Jun 1997

L3 ANSWER 18 OF 23 MEDLINE on STN
Full Text
AN 1997141156 MEDLINE
DN PubMed ID: 8987500
TI Succinoyl **trehalose** lipid induced differentiation of human monocytoid
leukemic cell line U937 into monocyte-macrophages.
AU Isoda H; Shinmoto H; Matsumura M; Nakahara T
CS Institute of Applied Biochemistry, University of Tsukuba, Ibaraki, Japan.
SO Cytotechnology, (1995-1996) Vol. 19, No. 1, pp. 79-88.
Journal code: 8807027. ISSN: 0920-9069.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Biotechnology
EM 199702
ED Entered STN: 27 Feb 1997
Last Updated on STN: 6 Feb 1998
Entered Medline: 13 Feb 1997

L3 ANSWER 19 OF 23 MEDLINE on STN
Full Text
AN 1997047678 MEDLINE
DN PubMed ID: 8926067
TI Synthesis, characterization, and immunologic properties of detoxified
lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to
proteins.
AU Gu X X; Tsai C M; Ueyama T; Barenkamp S J; Robbins J B; Lim D J
CS Vaccine Development Unit, Laboratory of Cellular Biology, National
Institute of Deafness and Other Communication Disorders, NIH, Rockville,
Maryland 20850, USA.. xgu@pop.nidcd.nih.gov
SO Infection and immunity, (1996 Oct) Vol. 64, No. 10, pp. 4047-53.
Journal code: 0246127. ISSN: 0019-9567.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199611
ED Entered STN: 19 Dec 1996
Last Updated on STN: 19 Dec 1996
Entered Medline: 14 Nov 1996

L3 ANSWER 20 OF 23 MEDLINE on STN
Full Text
AN 1994364496 MEDLINE
DN PubMed ID: 8082789
TI Predominant role of the substituents on the hydroxyl groups of 3-hydroxy
fatty acids of non-reducing glucosamine in lipid A for the endotoxic and
antagonistic activity.
AU Tanamoto K
CS National Institute of Health Sciences, Tokyo, Japan.
SO FEBS letters, (1994 Sep 12) Vol. 351, No. 3, pp. 325-9.
Journal code: 0155157. ISSN: 0014-5793.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199410
ED Entered STN: 21 Oct 1994
Last Updated on STN: 6 Feb 1998

Entered Medline: 13 Oct 1994

L3 ANSWER 21 OF 23 MEDLINE on STN

Full Text

AN 1993239291 MEDLINE

DN PubMed ID: 8478076

TI Preparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-protein conjugates.

AU Gu X X; Tsai C M

CS Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892.

SO Infection and immunity, (1993 May) Vol. 61, No. 5, pp. 1873-80. Journal code: 0246127. ISSN: 0019-9567.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199305

ED Entered STN: 11 Jun 1993

Last Updated on STN: 11 Jun 1993

Entered Medline: 24 May 1993

L3 ANSWER 22 OF 23 MEDLINE on STN

Full Text

AN 1990150159 MEDLINE

DN PubMed ID: 2620300

TI Chemical combination of 6-deoxy-6-mycoloylamino-alpha, alpha-trehalose and N-acetyl-6-O-(aminoacyl)muramoyl dipeptide.

AU Ishida H; Ogawa Y; Imai Y; Kiso M; Hasegawa A; Sakurai T; Azuma I

CS Department of Applied Bioorganic Chemistry, Gifu University, Japan.

SO Carbohydrate research, (1989 Dec 1) Vol. 194, pp. 199-208. Journal code: 0043535. ISSN: 0008-6215.

CY Netherlands

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199003

ED Entered STN: 1 Jun 1990

Last Updated on STN: 3 Feb 1997

Entered Medline: 27 Mar 1990

L3 ANSWER 23 OF 23 MEDLINE on STN

Full Text

AN 1981117691 MEDLINE

DN PubMed ID: 7007420

TI Variable assimilation of carbon compounds by Candida albicans.

AU Syverson R E

SO Journal of clinical microbiology, (1981 Jan) Vol. 13, No. 1, pp. 163-6. Journal code: 7505564. ISSN: 0095-1137.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 198104

ED Entered STN: 16 Mar 1990

Last Updated on STN: 3 Feb 1997

Entered Medline: 13 Apr 1981

=> file ca

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

5.86

6.07

FILE 'CA' ENTERED AT 20:32:50 ON 28 OCT 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Oct 2008 VOL 149 ISS 18
FILE LAST UPDATED: 26 Oct 2008 (20081026/ED)

CA now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 20:29:26 ON 28 OCT 2008)

FILE 'MEDLINE' ENTERED AT 20:30:04 ON 28 OCT 2008

L1 10476 S (DISACCHARIDE OR TREHALOSE OR CELLOBIOSE)
L2 4865 S (DIACID OR DI-ACID OR SUCCINIC ACID OR ADIPIC ACID OR GLUTARI
L3 23 S L1 AND L2

FILE 'CA' ENTERED AT 20:32:50 ON 28 OCT 2008

=> s (disaccharide or trehalose or cellobiose)/ab,bi

9534 DISACCHARIDE/AB
12476 DISACCHARIDE/BI
9075 TREHALOSE/AB
12629 TREHALOSE/BI
6347 CELLOBIOSE/AB
8418 CELLOBIOSE/BI
L4 31173 (DISACCHARIDE OR TREHALOSE OR CELLOBIOSE)/AB,BI

=> s (diacid or di-acid or succinic acid or adipic acid or glutaric acid or pimelic acid or s

5128 DIACID/AB
6779 DIACID/BI
325720 DI/AB
3013776 ACID/AB
237 DI-ACID/AB
((DI(W)ACID)/AB)
508491 DI/BI
4617845 ACID/BI
286 DI-ACID/BI
((DI(W)ACID)/BI)
36224 SUCCINIC/AB
3013776 ACID/AB
15662 SUCCINIC ACID/AB
((SUCCINIC(W)ACID)/AB)
67261 SUCCINIC/BI
4617845 ACID/BI
41968 SUCCINIC ACID/BI
((SUCCINIC(W)ACID)/BI)
24962 ADIPIC/AB
3013776 ACID/AB
21772 ADIPIC ACID/AB
((ADIPIC(W)ACID)/AB)
42154 ADIPIC/BI
4617845 ACID/BI
39590 ADIPIC ACID/BI
((ADIPIC(W)ACID)/BI)
5217 GLUTARIC/AB
3013776 ACID/AB
2515 GLUTARIC ACID/AB
((GLUTARIC(W)ACID)/AB)
14311 GLUTARIC/BI

```

4617845 ACID/BI
10770 GLUTARIC ACID/BI
      ((GLUTARIC(W)ACID)/BI)
1245 PIMELIC/AB
3013776 ACID/AB
      771 PIMELIC ACID/AB
          ((PIMELIC(W)ACID)/AB)
2535 PIMELIC/BI
4617845 ACID/BI
      2203 PIMELIC ACID/BI
          ((PIMELIC(W)ACID)/BI)
1277 SUBERIC/AB
3013776 ACID/AB
      709 SUBERIC ACID/AB
          ((SUBERIC(W)ACID)/AB)
2524 SUBERIC/BI
4617845 ACID/BI
      2147 SUBERIC ACID/BI
          ((SUBERIC(W)ACID)/BI)
3214 AZELAIC/AB
3013776 ACID/AB
      2315 AZELAIC ACID/AB
          ((AZELAIC(W)ACID)/AB)
5569 AZELAIC/BI
4617845 ACID/BI
      4935 AZELAIC ACID/BI
          ((AZELAIC(W)ACID)/BI)
6527 SEBACIC/AB
3013776 ACID/AB
      5151 SEBACIC ACID/AB
          ((SEBACIC(W)ACID)/AB)
11958 SEBACIC/BI
4617845 ACID/BI
      11005 SEBACIC ACID/BI
          ((SEBACIC(W)ACID)/BI)
L5      99646 (DIACID OR DI-ACID OR SUCCINIC ACID OR ADIPIC ACID OR GLUTARIC
            ACID OR PIMELIC ACID OR SUBERIC ACID OR AZELAIC ACID OR SEBACIC
            ACID)/AB,BI

=> d his

      (FILE 'HOME' ENTERED AT 20:29:26 ON 28 OCT 2008)

      FILE 'MEDLINE' ENTERED AT 20:30:04 ON 28 OCT 2008
L1      10476 S (DISACCHARIDE OR TREHALOSE OR CELLOBIOSE)
L2      4865 S (DIACID OR DI-ACID OR SUCCINIC ACID OR ADIPIC ACID OR GLUTARI
L3      23 S L1 AND L2

      FILE 'CA' ENTERED AT 20:32:50 ON 28 OCT 2008
L4      31173 S (DISACCHARIDE OR TREHALOSE OR CELLOBIOSE)/AB,BI
L5      99646 S (DIACID OR DI-ACID OR SUCCINIC ACID OR ADIPIC ACID OR GLUTARI

=> s 14 and 15
L6      480 L4 AND L5

=> s (surfactant)/ab,bi
      142457 (SURFACTANT)/AB
      201665 (SURFACTANT)/BI
L7      201665 (SURFACTANT)/AB,BI

=> s 16 and 17
L8      11 L6 AND L7

=> d 1-11

L8      ANSWER 1 OF 11  CA  COPYRIGHT 2008 ACS on STN
Full Text
AN      149:112411  CA
TI      Stable preparation of humanized anti-her2 antibody
IN      Wang, Hao; Guo, Yajun; Hou, Sheng; Kou, Geng; Qian, Weizhu; Li, Caihui
PA      Shanghai Zhongjian Biotechnology Research Institute, Peop. Rep. China
SO      Faming Zhuanli Shenqing Gongkai Shuomingshu, 8pp.

```

CODEN: CNXXEV

DT Patent

LA Chinese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 101199483	A	20080618	CN 2006-10147280	20061214
PRAI	CN 2006-10147280		20061214		

L8 ANSWER 2 OF 11 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 148:287239 CA

TI Alkyl- or alkenylsuccinic acid (salt) detergent compositions showing less trace after wiping for hard surfaces

IN Inoue, Takumi; Tsukuda, Kazunori

PA Kao Corp., Japan

SO Jpn. Kokai Tokkyo Koho, 15pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2008044993	A	20080228	JP 2006-219798	20060811
PRAI	JP 2006-219798		20060811		

L8 ANSWER 3 OF 11 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 146:487771 CA

TI Stable formulations containing enhancing proportions of gamma- and alpha-interferons

IN Bello Rivero, Iraldo; Lopez Saura, Pedro; Garcia Vega, Yanelda; Santana Milian, Hector; Aguilera Barreto, Ana; Paez Meireles, Rolando; Anasagasti Angulo, Lorenzo

PA Centro de Ingenieria Genetica y Biotecnologia, Cuba

SO PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DT Patent

LA Spanish

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007051431	A2	20070510	WO 2006-CU11	20061027
	WO 2007051431	A3	20070628		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	AU 2006310918	A1	20070510	AU 2006-310918	20061027
	CA 2629895	A1	20070510	CA 2006-2629895	20061027
	EP 1958643	A2	20080820	EP 2006-805254	20061027
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	MX 200805863	A	20080515	MX 2008-5863	20080502
	KR 2008065684	A	20080714	KR 2008-713121	20080530
PRAI	CU 2005-213	A	20051102		
	WO 2006-CU11	W	20061027		

L8 ANSWER 4 OF 11 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 146:50141 CA

TI Purification and pharmaceutical formulation of human blood-coagulation factor XI and its use to treat bleeding episodes

IN Jensen, Simon Bjerregaard; Viuff, Dorthe

PA Novo Nordisk A/S, Den.
 SO PCT Int. Appl., 96pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006128497	A1	20061207	WO 2005-EP52511	20050601
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI WO 2005-EP52511 20050601

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 11 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 145:74711 CA
 TI B-stageable underfill encapsulant and method for its application directly onto semiconductor wafers before dicing
 IN Xiao, Allison Yue; Tong, Quinn K.; Ma, Badan; Dutt, Gyanendra
 PA USA
 SO U.S. Pat. Appl. Publ., 12 pp., Cont.-in-part of U.S. Ser. No. 84,873.
 CODEN: USXXCO

DT Patent
 LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060125119	A1	20060615	US 2005-284219	20051121
	US 20030164555	A1	20030904	US 2002-84873	20020301
PRAI	US 2002-84873	A2	20020301		

L8 ANSWER 6 OF 11 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 144:219277 CA
 TI Microprojection apparatus and system with low infection potential
 IN Cormier, Michel J. N.; Daddona, Peter; Anderson, Rolfe
 PA USA
 SO U.S. Pat. Appl. Publ., 25 pp.
 CODEN: USXXCO

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060034902	A1	20060216	US 2005-201617	20050810
	AU 2005272701	A1	20060223	AU 2005-272701	20050810
	CA 2575532	A1	20060223	CA 2005-2575532	20050810
	WO 2006020842	A1	20060223	WO 2005-US28694	20050810
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

EP 1776156 A1 20070425 EP 2005-786621 20050810
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
 CN 101035589 A 20070912 CN 2005-80033663 20050810
 JP 2008509747 T 20080403 JP 2007-525819 20050810
 IN 2007DN00880 A 20070803 IN 2007-DN880 20070201
 MX 200701808 A 20071010 MX 2007-1808 20070212
 KR 2007050074 A 20070514 KR 2007-705605 20070309
 PRAI US 2004-600638P P 20040810
 WO 2005-US28694 W 20050810

L8 ANSWER 7 OF 11 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 143:40723 CA
 TI Surface activity and metabolism of hydrocarbon-degrading microorganisms
 growing on hexadecane and naphthalene
 AU Puntus, I. F.; Sakharovsky, V. G.; Filonov, A. E.; Boronin, A. M.
 CS G.K. Skryabin Institute of Biochemistry and Physiology of Microorganisms
 of the Russian Academy of Sciences, Pushchino, 142290, Russia
 SO Process Biochemistry (Oxford, United Kingdom) (2005), 40(8), 2643-2648
 CODEN: PBCHE5; ISSN: 1359-5113
 PB Elsevier Ltd.
 DT Journal
 LA English
 RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 11 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 140:64702 CA
 TI Detergent compositions containing taurine derivatives
 IN Kinoshita, Koichi; Noda, Akira; Fukuda, Toshio; Nakama, Yasunari; Kimura,
 Tomohiko
 PA Shiseido Company, Ltd., Japan
 SO PCT Int. Appl., 55 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000982	A1	20031231	WO 2003-JP1298	20030207
W: CN, KR, US				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR				
JP 2004026976	A	20040129	JP 2002-184157	20020625
JP 2003129097	A	20030508	JP 2002-226438	20020802
EP 1516914	A1	20050323	EP 2003-705054	20030207
EP 1516914	A9	20051102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, CY, TR, BG, CZ, EE, HU, SK				
CN 1665916	A	20050907	CN 2003-815138	20030207
US 20050176615	A1	20050811	US 2004-517147	20041207
PRAI JP 2002-184157	A	20020625		
JP 2002-226438	A	20020802		
JP 2001-243518	A	20010810		
WO 2003-JP1298	W	20030207		

OS MARPAT 140:64702
 RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 11 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 138:95254 CA
 TI Foaming compositions containing silica and cationic polymers
 IN Sebillotte-Arnaud, Laurence; Bordeaux, Dominique
 PA L'oreal, Fr.
 SO Eur. Pat. Appl., 28 pp.
 CODEN: EPXXDW
 DT Patent
 LA French
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1277463	A1	20030122	EP 2002-291580	20020625
	EP 1277463	B1	20080102		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	FR 2827515	A1	20030124	FR 2001-9767	20010720
	FR 2827515	B1	20050603		
	AT 382324	T	20080115	AT 2002-291580	20020625
	CN 1398581	A	20030226	CN 2002-126519	20020719
	JP 2003113073	A	20030418	JP 2002-212920	20020722
	US 20030134761	A1	20030717	US 2002-199177	20020722
	US 6894012	B2	20050517		
PRAI	FR 2001-9767	A	20010720		
RE.CNT	8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD				
	ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L8 ANSWER 10 OF 11 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 127:86136 CA

OREF 127:16453a,16456a

TI A calcitonin preparation

IN Byrne, William; O'Driscoll, Caitriona M.; Corrigan, Owen I.

PA Dullatur Ltd., Ire.

SO PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9721448	A1	19970619	WO 1996-IE86	19961213
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9718088	A	19970703	AU 1997-18088	19961213
	ZA 9610545	A	19970624	ZA 1996-10545	19961223
PRAI	IE 1995-940	A	19951213		
	WO 1996-IE86	W	19961213		

L8 ANSWER 11 OF 11 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 115:23905 CA

OREF 115:4124h,4125a

TI Toxicity testing of synthetic and biogenic surfactants on marine microorganisms

AU Poremba, K.; Gunkel, W.; Lang, S.; Wagner, F.

CS Dep. Mar. Microbiol., Biol. Anstalt Helgoland, Helgoland, D-2192, Germany

SO Environmental Toxicology and Water Quality (1991), 6(2), 157-63

CODEN: ETWQEZ; ISSN: 1053-4725

DT Journal

LA English

=> d an ti pa so pi ab kwic 9 10

L8 ANSWER 9 OF 11 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 138:95254 CA

TI Foaming compositions containing silica and cationic polymers

PA L'oreal, Fr.

SO Eur. Pat. Appl., 28 pp.

CODEN: EPXXDW

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1277463	A1	20030122	EP 2002-291580	20020625
	EP 1277463	B1	20080102		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

FR 2827515	A1	20030124	FR 2001-9767	20010720
FR 2827515	B1	20050603		
AT 382324	T	20080115	AT 2002-291580	20020625
CN 1398581	A	20030226	CN 2002-126519	20020719
JP 2003113073	A	20030418	JP 2002-212920	20020722
US 20030134761	A1	20030717	US 2002-199177	20020722
US 6894012	B2	20050517		

AB A cleansing compn. comprises a foaming **surfactant**, a silica, an oxyalkylene compd., and a cationic and amphoteric polymer. Formulations of cosmetic foams comprising above ingredients are disclosed.

AB A cleansing compn. comprises a foaming **surfactant**, a silica, an oxyalkylene compd., and a cationic and amphoteric polymer. Formulations of cosmetic foams comprising above ingredients are disclosed.

IT 50-21-5, Lactic acid, biological studies 50-81-7, Vitamin C, biological studies 53-00-9 53-43-0, DHEA 56-40-6D, Glycine, derivs. 56-45-1, Serine, biological studies 56-81-5, Glycerin, biological studies 56-81-5D, Glycerol, triesters 57-13-6, Urea, biological studies 69-72-7, Salicylic acid, biological studies 69-72-7D, Salicylic acid, derivs. 69-79-4D, Maltose, esters 77-52-1, Ursolic acid 77-92-9, Citric acid, biological studies 79-10-7D, Acrylic acid, polymers with vinylpyrrolidone 79-14-1, Glycolic acid, biological studies 79-41-4D, MethAcrylic acid, polymers with vinylpyrrolidone 87-99-0, Xylitol 88-12-0D, polymers with acrylates 94-36-0, Benzoyl peroxide, biological studies 98-79-3, Pyrrolidone carboxylic acid 98-92-0, Vitamin B3 99-20-7, **Trehalose** 101-20-2, Triclocarban 107-35-7D, derivs. 107-36-8D, Isethionic acid, derivs. 123-43-3D, Sulfoacetic acid, alkyl derivs. 123-99-9, **Azelaic acid**, biological studies 303-98-0, Coenzyme Q10 471-53-4, Glycyrrhetic acid 488-43-7D, Glucamine, derivs. 492-61-5D, β -D-Glucopyranose, cocoacyl derivs. 822-06-0, Hexamethylene diisocyanate 1406-18-4, Vitamin E 2627-35-2 3380-34-5, Triclosan 3991-73-9D, esters 5138-18-1D, Sulfosuccinic acid, derivs. 7235-40-7, β -Carotene 7631-86-9, Silica, biological studies 7664-38-2D, Phosphoric acid, alkyl potassium or triethanolamine salts 9000-30-0, Guar gum 9003-11-6, Ethylene Oxide propylene oxide copolymer 9004-34-6D, Cellulose, quaternary derivs. 9004-61-9, Hyaluronic acid 9005-00-9 9005-05-4 9005-08-7, Polyethylene glycol distearate 9012-76-4, Chitosan 11103-57-4, Vitamin A 11104-38-4, Vitamin K1 25136-75-8, POLYQUATERNIUM39 25322-68-3 25322-68-3D, Polyethylene glycol, derives 25322-69-4, Polypropylene glycol 25322-69-4D, Polypropylene glycol, derives 25568-39-2D, quaternary derivs. 26006-22-4, Acrylamide-methacryloyloxy-ethyltrimethylammonium methosulfate copolymer 26062-79-3, Polydimethyldiallyl ammonium chloride 26590-05-6, Acrylamide-dimethyldiallyl ammonium chloride copolymer 27836-64-2, Laurylglucoside 29297-55-0D, Vinylpyrrolidone-vinylimidazole copolymer, quaternary derivs. 29836-26-8 35429-19-7, Acrylamide-methacryloyloxyethyltrimethyl-ammonium chloride copolymer 36493-27-3 39322-78-6, Potassium lauryl phosphate 39421-75-5D, Hydroxypropyl guar, trialkylammonium derivs. 51987-20-3 58846-77-8, Decylglucoside 59080-45-4 65045-37-6, Potassium dodecylphosphate 86893-19-8, Glucamate DOE 120 96702-03-3, Ectoine 102972-64-5 127252-82-8 130249-48-8 131954-48-8, POLYQUATERNIUM28 150599-70-5, POLYQUA-TERNIUM44 197969-51-0, Polyquaternium 47 278184-48-8, Mydol 10 484674-87-5

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(foaming compns. contg. silica and cationic polymers)

L8 ANSWER 10 OF 11 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 127:86136 CA
OREF 127:16453a,16456a
TI A calcitonin preparation
PA Dullatur Ltd., Ire.
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9721448	A1	19970619	WO 1996-IE86	19961213
	W:				
	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				

RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
 IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,
 MR, NE, SN, TD, TG

AU 9718088 A 19970703 AU 1997-18088 19961213
 ZA 9610545 A 19970624 ZA 1996-10545 19961223

AB An oral calcitonin prepn. includes an absorption enhancer and, optionally,
 a protease enzyme inhibitor. The enzyme inhibitor is selected from
 aprotinin, potato carboxypeptidase inhibitor, and chymostatin. The
 enhancer may be a bile acid or salt thereof, esp. sodium glycocholate,
 sodium cholate or sodium deoxycholate. Alternatively the enhancer may be
 a non-ionic **surfactant**, preferably a polyoxyethyleneglycerol
 triricinoleate deriv. The enhancer may also be a cyclodextrin or its
 derivs. such as a hydroxypropylbetacyclodextrin.

AB . . . bile acid or salt thereof, esp. sodium glycocholate, sodium
 cholate or sodium deoxycholate. Alternatively the enhancer may be a
 non-ionic **surfactant**, preferably a polyoxyethyleneglycerol
 triricinoleate deriv. The enhancer may also be a cyclodextrin or its
 derivs. such as a hydroxypropylbetacyclodextrin.

IT 50-99-7, Glucose, biological studies 63-42-3, Lactose 69-65-8,
 Mannitol 77-92-9, Citric acid, biological studies 81-24-3, Taurocholic
 acid 81-25-4, Cholic acid 83-44-3, Deoxycholic acid 87-69-4,
 Tartaric acid, biological studies 99-20-7, **Trehalose**
 110-15-6, **Succinic acid**, biological studies
 128-13-2, Ursodeoxycholic acid 302-95-4, Sodium deoxycholate 361-09-1,
 Sodium cholate 474-25-9, Chenodeoxycholic acid 475-31-0, Glycocholic
 acid 863-57-0, Sodium glycocholate 7585-39-9D, β -Cyclodextrin,
 Hydroxypropyl derivs. 9076-44-2, Chymostatin 9087-70-1, Aprotinin
 12619-70-4D, Cyclodextrin, derivs. 25322-68-3, Polyethylene glycol
 37205-61-1, Protease inhibitor 39311-00-7D, derivs. 159745-68-3,
 Potato carboxypeptidase inhibitor
 RL: MOA (Modifier or additive use); PEP (Physical, engineering or chemical
 process); THU (Therapeutic use); BIOL (Biological study); PROC (Process);
 USES (Uses)
 (formulation of an oral calcitonin prepn.)

=> file uspatall
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
106.16	112.23

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-1.50	-1.50

CA SUBSCRIBER PRICE

FILE 'USPATFULL' ENTERED AT 20:36:21 ON 28 OCT 2008
 CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 20:36:21 ON 28 OCT 2008
 CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 20:36:21 ON 28 OCT 2008
 CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s (disaccharide or trehalose or cellobiose)
 COMMAND INTERRUPTED

1 FILES SEARCHED...

If this message appears repeatedly, please notify the Help Desk.
 Enter "HELP STN" for information on contacting the nearest STN Help
 Desk by telephone or via SEND in the STNMAIL file.

=> s (disaccharide or trehalose or cellobiose)
 COMMAND INTERRUPTED

1 FILES SEARCHED...

If this message appears repeatedly, please notify the Help Desk.
 Enter "HELP STN" for information on contacting the nearest STN Help
 Desk by telephone or via SEND in the STNMAIL file.

=> s (disaccharide or trehalose or cellobiose)/clm
 L9 4035 (DISACCHARIDE OR TREHALOSE OR CELLOBIOSE)/CLM

```

=> s (diacid or di-acid or succinic acid or adipic acid or glutaric acid or pimelic acid or s
L10      143560 (DIACID OR DI-ACID OR SUCCINIC ACID OR ADIPIC ACID OR GLUTARIC
          ACID OR PIMELIC ACID OR SUBERIC ACID OR AZELAIC ACID OR SEBACIC
          ACID)

=> s (diacid or di-acid or succinic acid or adipic acid or glutaric acid or pimelic acid or s
L11      18508 (DIACID OR DI-ACID OR SUCCINIC ACID OR ADIPIC ACID OR GLUTARIC
          ACID OR PIMELIC ACID OR SUBERIC ACID OR AZELAIC ACID OR SEBACIC
          ACID)/CLM

=> s (disaccharide or trehalose or cellobiose)
L12      31389 (DISACCHARIDE OR TREHALOSE OR CELLOBIOSE)

=> d his

      (FILE 'HOME' ENTERED AT 20:29:26 ON 28 OCT 2008)

      FILE 'MEDLINE' ENTERED AT 20:30:04 ON 28 OCT 2008
L1      10476 S (DISACCHARIDE OR TREHALOSE OR CELLOBIOSE)
L2      4865 S (DIACID OR DI-ACID OR SUCCINIC ACID OR ADIPIC ACID OR GLUTARI
L3      23 S L1 AND L2

      FILE 'CA' ENTERED AT 20:32:50 ON 28 OCT 2008
L4      31173 S (DISACCHARIDE OR TREHALOSE OR CELLOBIOSE)/AB,BI
L5      99646 S (DIACID OR DI-ACID OR SUCCINIC ACID OR ADIPIC ACID OR GLUTARI
L6      480 S L4 AND L5
L7      201665 S (SURFACTANT)/AB,BI
L8      11 S L6 AND L7

      FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 20:36:21 ON 28 OCT 2008
L9      4035 S (DISACCHARIDE OR TREHALOSE OR CELLOBIOSE)/CLM
L10     143560 S (DIACID OR DI-ACID OR SUCCINIC ACID OR ADIPIC ACID OR GLUTARI
L11     18508 S (DIACID OR DI-ACID OR SUCCINIC ACID OR ADIPIC ACID OR GLUTARI
L12     31389 S (DISACCHARIDE OR TREHALOSE OR CELLOBIOSE)

=> s 19 and 111
L13     124 L9 AND L11

=> s 110 and 112
L14     5250 L10 AND L12

=> s (surfactant)
L15     197387 (SURFACTANT)

=> s (surfactant)/clm
L16     52521 (SURFACTANT)/CLM

=> s 113 and 116
L17     41 L13 AND L16

=> s 114 and 115
L18     2455 L14 AND L15

=> d 117 1-41

L17 ANSWER 1 OF 41  USPATFULL on STN
Full Text
AN      2008:220507  USPATFULL
TI      Hair Treatment Composition
IN      Bell, Fraser Ian, Wirral, UNITED KINGDOM
        Pratley, Stuart Keith, Merseyside, UNITED KINGDOM
        Skinner, Richard, Wirral, UNITED KINGDOM
PI      US 20080193401      A1  20080814
AI      US 2005-547576      A1  20050323 (11)
        WO 2005-EP3245      20050323
                        20071220  PCT 371 date
PRAI    EP 2004-252059      20040407
        EP 2004-252982      20040521
DT      Utility
FS      APPLICATION
LN.CNT  601
INCL    INCLM: 424/070.100

```

NCL NCLM: 424/070.100
IC IPCI A61K0008-30 [I,A]; A61Q0005-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 2 OF 41 USPATFULL on STN

Full Text

AN 2008:143092 USPATFULL
TI Stable polypeptide formulations
IN Rehder, Douglas, Seattle, WA, UNITED STATES
Bondarenko, Pavel, Thousand Oaks, CA, UNITED STATES
Chelius, Dirk, Geretsried, GERMANY, FEDERAL REPUBLIC OF
McAuley, Arnold, Moorpark, CA, UNITED STATES
Matsumura, Masazumi, Thousand Oaks, CA, UNITED STATES
PA Amgen Inc., Thousand Oaks, CA, UNITED STATES (U.S. corporation)
PI US 20080124326 A1 20080529
AI US 2007-973051 A1 20071005 (11)
PRAI US 2006-853181P 20061020 (60)
DT Utility
FS APPLICATION
LN.CNT 2565
INCL INCLM: 424/133.100
INCLS: 424/158.100; 424/143.100; 530/389.200
NCL NCLM: 424/133.100
NCLS: 424/143.100; 424/158.100; 530/389.200
IC IPCI A61K0039-395 [I,A]; C07K0016-28 [I,A]; C07K0016-18 [I,C*]
IPCR A61K0039-395 [I,C]; A61K0039-395 [I,A]; C07K0016-18 [I,C];
C07K0016-28 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 3 OF 41 USPATFULL on STN

Full Text

AN 2008:129990 USPATFULL
TI Stable formulations
IN McAuley, Arnold, Moorpark, CA, UNITED STATES
Rehder, Douglas, Seattle, WA, UNITED STATES
Matsumura, Masazumi, Thousand Oaks, CA, UNITED STATES
PA Amgen Inc., Thousand Oaks, CA, UNITED STATES (U.S. corporation)
PI US 20080112953 A1 20080515
AI US 2007-973200 A1 20071005 (11)
PRAI US 2006-850362P 20061006 (60)
US 2006-850970P 20061010 (60)
DT Utility
FS APPLICATION
LN.CNT 2116
INCL INCLM: 424/133.100
INCLS: 424/145.100
NCL NCLM: 424/133.100
NCLS: 424/145.100
IC IPCI A61K0039-395 [I,A]
IPCR A61K0039-395 [I,C]; A61K0039-395 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 4 OF 41 USPATFULL on STN

Full Text

AN 2008:118424 USPATFULL
TI CEPHALOSPORIN DERIVATIVE FORMULATION
IN Gole, Dilip Jagannath, Plainsboro, NJ, UNITED STATES
Amin, Ketan, Randolph, NJ, UNITED STATES
Jimidar, M. llias, Turnhout, BELGIUM
Vermeersch, Hans, Gent, BELGIUM
Tran, Michael, Cheltenham, PA, UNITED STATES
PI US 20080103121 A1 20080501
AI US 2007-874405 A1 20071018 (11)
PRAI US 2006-855240P 20061030 (60)
DT Utility
FS APPLICATION
LN.CNT 1234
INCL INCLM: 514/202.000
NCL NCLM: 514/202.000
IC IPCI A61K0031-546 [I,A]; A61P0031-04 [I,A]; A61P0031-00 [I,C*]
IPCR A61K0031-546 [I,C]; A61K0031-546 [I,A]; A61P0031-00 [I,C];
A61P0031-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 5 OF 41 USPATFULL on STN

Full Text

AN 2007:249502 USPATFULL
TI Sustained release matrix systems for highly soluble drugs
IN Baichwal, Anand R., Wappingers Falls, NY, UNITED STATES
McCall, Troy W., Germantown, TN, UNITED STATES
Liu, Lirong, Washington Township, NJ, UNITED STATES
Labudzinski, Steve, Poughkeepsie, NY, UNITED STATES
PA Penwest Pharmaceuticals Co., Danbury, CT, UNITED STATES, 06810-5120
(U.S. corporation)
PI US 20070218137 A1 20070920
AI US 2007-729024 A1 20070327 (11)
RLI Continuation of Ser. No. US 2003-740213, filed on 18 Dec 2003, PENDING
Continuation of Ser. No. US 2000-676376, filed on 29 Sep 2000, ABANDONED
PRAI US 1999-157200P 19990930 (60)
DT Utility
FS APPLICATION
LN.CNT 2154
INCL INCLM: 424/485.000
NCL NCLM: 424/485.000
IC IPCI A61K0009-00 [I,A]
IPCR A61K0009-00 [I,C]; A61K0009-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 6 OF 41 USPATFULL on STN

Full Text

AN 2007:237581 USPATFULL
TI Stabilised solid compositions of factor VII polypeptides
IN Jensen, Michael Bech, Allerod, DENMARK
Hansen, Birthe Lykkegaard, Vaerloose, DENMARK
Kornfelt, Troels, Virum, DENMARK
PA Novo Nordisk HealthCare A/G, Zurich, SWITZERLAND (non-U.S. corporation)
PI US 20070207956 A1 20070906
AI US 2006-526503 A1 20060925 (11)
RLI Continuation of Ser. No. US 2003-609780, filed on 30 Jun 2003, ABANDONED
PRAI DK 2002-963 20020621
WO 2003-DK419 20030620
US 2002-394153P 20020703 (60)
DT Utility
FS APPLICATION
LN.CNT 1763
INCL INCLM: 514/012.000
NCL NCLM: 514/012.000
IC IPCI A61K0038-36 [I,A]
IPCR A61K0038-36 [I,C]; A61K0038-36 [I,A]; A61K0038-43 [I,C*];
A61K0038-48 [I,A]; A61K0047-02 [I,C*]; A61K0047-02 [I,A];
A61K0047-16 [I,C*]; A61K0047-18 [I,A]; A61K0047-26 [I,C*];
A61K0047-26 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 7 OF 41 USPATFULL on STN

Full Text

AN 2007:120577 USPATFULL
TI Controlled-release emulsion compositions
IN Zeng, Hongxia, Newtown, CT, UNITED STATES
Moroni, Antonio, Morris Plains, NJ, UNITED STATES
Baichwal, Anand R., Wappingers Falls, NY, UNITED STATES
Goliber, Philip A., Brookfield, CT, UNITED STATES
Ketsela, Sara, Danbury, CT, UNITED STATES
McNamara, Daniel P., Waterbury, CT, UNITED STATES
PI US 20070104778 A1 20070510
AI US 2006-594329 A1 20061107 (11)
PRAI US 2005-734198P 20051107 (60)
DT Utility
FS APPLICATION
LN.CNT 2665
INCL INCLM: 424/451.000
INCLS: 424/468.000; 514/217.000; 514/355.000; 514/411.000; 424/731.000
NCL NCLM: 424/451.000
NCLS: 424/468.000; 424/731.000; 514/217.000; 514/355.000; 514/411.000

IC IPCI A61K0036-47 [I,A]; A61K0036-185 [I,C*]; A61K0031-55 [I,A];
A61K0009-22 [I,A]; A61K0009-48 [I,A]; A61K0031-455 [I,A];
A61K0031-403 [I,A]
IPCR A61K0036-185 [I,C]; A61K0036-47 [I,A]; A61K0009-22 [I,C];
A61K0009-22 [I,A]; A61K0009-48 [I,C]; A61K0009-48 [I,A];
A61K0031-403 [I,C]; A61K0031-403 [I,A]; A61K0031-455 [I,C];
A61K0031-455 [I,A]; A61K0031-55 [I,C]; A61K0031-55 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 8 OF 41 USPATFULL on STN

Full Text

AN 2007:24293 USPATFULL
TI Stabilised compositions of Factor VII
IN Hansen, Birthe Lykkegaard, Vaerloose, DENMARK
Jensen, Michael Bech, Allerod, DENMARK
Kornfelt, Troels, Virum, DENMARK
PA Novo Nordisk HealthCare A/G, Zurich, SWITZERLAND (non-U.S. corporation)
PI US 20070021338 A1 20070125
AI US 2006-450783 A1 20060609 (11)
RLI Continuation of Ser. No. WO 2004-EP53587, filed on 17 Dec 2004, UNKNOWN
PRAI DK 2003-1901 20031219
DT Utility
FS APPLICATION
LN.CNT 2993
INCL INCLM: 514/012.000
INCLS: 514/018.000
NCL NCLM: 514/012.000
NCLS: 514/018.000
IC IPCI A61K0038-36 [I,A]; A61K0038-05 [I,A]
IPCR A61K0038-36 [I,C]; A61K0038-36 [I,A]; A61K0009-19 [I,C*];
A61K0009-19 [I,A]; A61K0038-05 [I,C]; A61K0038-05 [I,A];
A61K0038-37 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
A61K0047-16 [I,C*]; A61K0047-18 [I,A]; A61K0047-26 [I,C*];
A61K0047-26 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 9 OF 41 USPATFULL on STN

Full Text

AN 2006:227700 USPATFULL
TI Underfill encapsulant for wafer packaging and method for its application
IN Xiao, Allison Yue, Belle Mead, NJ, UNITED STATES
Dutt, Gyanendra, Piscataway, NJ, UNITED STATES
PI US 20060194064 A1 20060831
AI US 2006-351647 A1 20060210 (11)
RLI Continuation-in-part of Ser. No. US 2002-84869, filed on 1 Mar 2002,
GRANTED, Pat. No. US 7037399
DT Utility
FS APPLICATION
LN.CNT 721
INCL INCLM: 428/414.000
INCLS: 438/127.000; 523/400.000
NCL NCLM: 428/414.000
NCLS: 257/E21.503; 257/E23.119; 438/127.000; 523/400.000
IC IPCI B32B0027-38 [I,A]; H01L0021-56 [I,A]; H01L0021-02 [I,C*];
C08L0063-00 [I,A]; B32B0037-00 [N,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 10 OF 41 USPATFULL on STN

Full Text

AN 2006:214636 USPATFULL
TI Apparatus and method for transdermal delivery of epoetin-based agents
IN Ameri, Mahmoud, Fremont, CA, UNITED STATES
Cormier, Michel J.N., Mountain View, CA, UNITED STATES
Maa, Yuh-Fun, Millbrae, CA, UNITED STATES
Daddona, Peter, Menlo Park, CA, UNITED STATES
PI US 20060182789 A1 20060817
AI US 2006-355856 A1 20060215 (11)
PRAI US 2005-653676P 20050216 (60)
DT Utility
FS APPLICATION
LN.CNT 1787
INCL INCLM: 424/448.000

INCLS: 514/012.000; 604/500.000
NCL NCLM: 424/448.000
NCLS: 514/012.000; 604/500.000
IC IPCI A61K0038-18 [I,A]; A61F0013-02 [I,A]; A61M0031-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 11 OF 41 USPATFULL on STN

Full Text

AN 2006:148694 USPATFULL
TI B-stageable underfill encapsulant and method for its application
IN Xiao, Allison Yue, Belle Mead, NJ, UNITED STATES
Tong, Quinn K., Belle Mead, NJ, UNITED STATES
Ma, Badan, Racine, WI, UNITED STATES
Dutt, Gyanendra, Piscataway, NJ, UNITED STATES
PI US 20060125119 A1 20060615
AI US 2005-284219 A1 20051121 (11)
RLI Continuation-in-part of Ser. No. US 2002-84873, filed on 1 Mar 2002,
PENDING
DT Utility
FS APPLICATION
LN.CNT 922
INCL INCLM: 257/793.000
NCL NCLM: 257/793.000
NCLS: 257/E21.503; 257/E23.119
IC IPCI H01L0023-29 [I,A]; H01L0023-28 [I,C*]
IPCR C08K0003-00 [I,C*]; C08K0003-00 [I,A]; H01L0023-28 [I,C];
H01L0023-29 [I,A]; C08G0059-00 [I,C*]; C08G0059-20 [I,A];
C08G0059-50 [I,A]; C08G0059-62 [I,A]; C08G0059-68 [I,A];
C08K0005-00 [I,C*]; C08K0005-00 [I,A]; C08L0063-00 [I,C*];
C08L0063-00 [I,A]; H01L0021-02 [I,C*]; H01L0021-56 [I,A];
H01L0023-31 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 12 OF 41 USPATFULL on STN

Full Text

AN 2006:110716 USPATFULL
TI Apparatus and method for transdermal delivery of desmopressin
IN Sathyan, Gayatri, San Jose, CA, UNITED STATES
Weyers, Richard, Los Altos, CA, UNITED STATES
Daddona, Peter, Menlo Park, CA, UNITED STATES
Staehr, Peter, Mountain View, CA, UNITED STATES
Gupta, Suneel, Sunnyvale, CA, UNITED STATES
Ameri, Mahmound, Fremont, CA, UNITED STATES
Cormier, Michel J.N., Mountain View, CA, UNITED STATES
PI US 20060093658 A1 20060504
AI US 2005-259010 A1 20051025 (11)
PRAI US 2004-622467P 20041026 (60)
DT Utility
FS APPLICATION
LN.CNT 1800
INCL INCLM: 424/448.000
INCLS: 604/500.000
NCL NCLM: 424/448.000
NCLS: 604/500.000
IC IPCI A61F0013-02 [I,A]; A61M0031-00 [I,A]
IPCR A61F0013-02 [I,A]; A61F0013-02 [I,C]; A61M0031-00 [I,C];
A61M0031-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 13 OF 41 USPATFULL on STN

Full Text

AN 2006:86110 USPATFULL
TI Hair treatment compositions
IN Cornwell, Paul Alfred, Bebington, Wirral, UNITED KINGDOM
Hull, Peter James, Knutsford, UNITED KINGDOM
Skinner, Richard, Bebington, Wirral, UNITED KINGDOM
Devine, Karen Maria, Bebington, Wirral, UNITED KINGDOM
PI US 20060073109 A1 20060406
AI US 2003-538360 A1 20031126 (10)
WO 2003-EP13701 20031126
20050613 PCT 371 date
PRAI EP 2002-258604 20021213

DT Utility
FS APPLICATION
LN.CNT 532
INCL INCLM: 424/070.130
INCLS: 424/070.100
NCL NCLM: 424/070.130
NCLS: 424/070.100
IC IPCI A61K0008-00 [I,A]; A61K0008-73 [I,A]; A61K0008-72 [I,C*]
IPCR A61K0008-00 [I,A]; A61K0008-00 [I,C]; A61K0008-30 [I,C*];
A61K0008-362 [I,A]; A61K0008-60 [I,A]; A61K0008-72 [I,C];
A61K0008-73 [I,A]; A61Q0005-02 [I,C*]; A61Q0005-02 [I,A];
A61Q0005-12 [I,C*]; A61Q0005-12 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 14 OF 41 USPATFULL on STN

Full Text

AN 2006:63044 USPATFULL
TI Fabric care composition and method comprising a fabric care
polysaccharide and wrinkle control agent
IN Barnabas, Mary Vijayarani, West Chester, OH, UNITED STATES
Trinh, Toan, Maineville, OH, UNITED STATES
Barnabas, Freddy Arthur, West Chester, OH, UNITED STATES
Showell, Michael Stanford, Cincinnati, OH, UNITED STATES
Sine, Mark Richard, Morrow, OH, UNITED STATES
Smets, Johan, Lubbeek, BELGIUM
Tordil, Helen Bernado, West Chester, OH, UNITED STATES
Wernicke, Todd Michael, Cincinnati, OH, UNITED STATES
PA The Procter & Gamble Company, Cincinnati, OH, UNITED STATES (U.S.
corporation)
PI US 7012053 B1 20060314
WO 2000024856 20000504
AI US 1999-807367 19991022 (9)
WO 1999-US24942 19991022
20010412 PCT 371 date

DT Utility
FS GRANTED
LN.CNT 7483
INCL INCLM: 510/287.000
INCLS: 510/276.000; 510/292.000; 510/308.000; 510/322.000; 510/327.000;
510/382.000; 510/101.000; 510/394.000; 510/470.000; 510/515.000;
510/520.000
NCL NCLM: 510/287.000
NCLS: 510/101.000; 510/276.000; 510/292.000; 510/308.000; 510/322.000;
510/327.000; 510/382.000; 510/394.000; 510/470.000; 510/515.000;
510/520.000
IC IPCI C11D0003-22 [I,A]
IPCR C11D0003-22 [I,A]; C11D0003-22 [I,C]
EXF 510/276; 510/287; 510/292; 510/308; 510/322; 510/327; 510/382; 510/101;
510/394; 510/470; 510/515; 510/520
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 15 OF 41 USPATFULL on STN

Full Text

AN 2006:40256 USPATFULL
TI Apparatus and method for transdermal delivery of natriuretic peptides
IN Maa, Yuh-Fun, Millbrae, CA, UNITED STATES
Sellers, Scott, San Mateo, CA, UNITED STATES
Daddona, Peter, Menlo Park, CA, UNITED STATES
Kamberi, Marika, San Jose, CA, UNITED STATES
Gopalakrishnan, Vidhya, San Jose, CA, UNITED STATES
Silber, B. Michael, Palo Alto, CA, UNITED STATES
Stonebanks, Frank, Wayne, PA, UNITED STATES
PI US 20060034903 A1 20060216
AI US 2005-201625 A1 20050810 (11)
PRAI US 2004-600560P 20040811 (60)
DT Utility
FS APPLICATION
LN.CNT 1936
INCL INCLM: 424/448.000
INCLS: 514/012.000; 604/500.000
NCL NCLM: 424/448.000
NCLS: 514/012.000; 604/500.000

IC IPCI A61K0038-17 [I,A]; A61M0031-00 [I,A]; A61F0013-02 [I,A]
IPCR A61K0038-17 [I,A]; A61F0013-02 [I,C]; A61F0013-02 [I,A];
A61K0038-17 [I,C]; A61M0031-00 [I,C]; A61M0031-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 16 OF 41 USPATFULL on STN

Full Text

AN 2006:40255 USPATFULL
TI Microprojection apparatus and system with low infection potential
IN Cormier, Michel J.N., Mountain View, CA, UNITED STATES
Daddona, Peter, Menlo Park, CA, UNITED STATES
Anderson, Rolfe, Saratoga, CA, UNITED STATES
PI US 20060034902 A1 20060216
AI US 2005-201617 A1 20050810 (11)
PRAI US 2004-600638P 20040810 (60)
DT Utility
FS APPLICATION
LN.CNT 1903
INCL INCLM: 424/448.000
INCLS: 604/500.000
NCL NCLM: 424/448.000
NCLS: 604/500.000
IC IPCI A61F0013-02 [I,A]; A61L0015-16 [I,A]
IPCR A61F0013-02 [I,A]; A61F0013-02 [I,C]; A61L0015-16 [I,C];
A61L0015-16 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 17 OF 41 USPATFULL on STN

Full Text

AN 2006:35036 USPATFULL
TI Method and device for enhancing transdermal agent flux
IN Wong, Patrick S.L., Burlingame, CA, UNITED STATES
Daddona, Peter, Menlo Park, CA, UNITED STATES
PI US 20060030811 A1 20060209
AI US 2004-910915 A1 20040803 (10)
DT Utility
FS APPLICATION
LN.CNT 1229
INCL INCLM: 604/046.000
INCLS: 424/422.000
NCL NCLM: 604/046.000
NCLS: 424/422.000
IC IPCI A61B0017-20 [I,A]
IPCR A61B0017-20 [I,A]; A61B0017-20 [I,C]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 18 OF 41 USPATFULL on STN

Full Text

AN 2005:293496 USPATFULL
TI Apparatus and method for transdermal delivery of parathyroid hormone
agents
IN Ameri, Mahmoud, Fremont, CANADA
Cormier, Michel J.N., Mountain View, CA, UNITED STATES
Maa, Yuh-Fun, Millbrae, CANADA
Kamberi, Marika, San Jose, CA, UNITED STATES
Daddona, Peter, Menlo Park, CA, UNITED STATES
PI US 20050256045 A1 20051117
AI US 2005-84634 A1 20050318 (11)
PRAI US 2004-571304P 20040513 (60)
US 2004-585276P 20040701 (60)
US 2005-643660P 20050112 (60)
DT Utility
FS APPLICATION
LN.CNT 2112
INCL INCLM: 514/012.000
INCLS: 604/500.000
NCL NCLM: 514/012.000
NCLS: 604/500.000
IC [7]
ICM A61K038-29
ICS A61M031-00
IPCI A61K0038-29 [ICM,7]; A61M0031-00 [ICS,7]

IPCR A61K0009-00 [I,C*]; A61K0009-00 [I,A]; A61K0038-29 [I,C*];
A61K0038-29 [I,A]; A61K0047-12 [N,C*]; A61K0047-12 [N,A];
A61K0047-16 [N,C*]; A61K0047-18 [N,A]; A61K0047-26 [N,C*];
A61K0047-26 [N,A]; A61M0031-00 [I,C*]; A61M0031-00 [I,A];
A61M0037-00 [I,C*]; A61M0037-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 19 OF 41 USPATFULL on STN

Full Text

AN 2005:260901 USPATFULL
TI Apparatus and method for transdermal delivery of fentanyl-based agents
IN Ameri, Mahmoud, Fremont, CA, UNITED STATES
Cormier, Michel J.N., Mountain View, CA, UNITED STATES
Maa, Yuh-Fun, Millbrae, CA, UNITED STATES
Daddona, Peter, Menlo Park, CA, UNITED STATES
PI US 20050226922 A1 20051013
AI US 2005-84636 A1 20050318 (11)
PRAI US 2004-561949P 20040413 (60)
DT Utility
FS APPLICATION
LN.CNT 1907
INCL INCLM: 424/449.000
INCLS: 514/317.000
NCL NCLM: 424/449.000
NCLS: 514/317.000
IC [7]
ICM A61K031-445
ICS A61K009-70
IPCI A61K0031-445 [ICM,7]; A61K0009-70 [ICS,7]
IPCR A61K0009-70 [I,C*]; A61K0009-70 [I,A]; A61K0031-445 [I,C*];
A61K0031-445 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 20 OF 41 USPATFULL on STN

Full Text

AN 2005:177792 USPATFULL
TI Frequency assisted transdermal agent delivery method and system
IN Chan, Keith T., Sunnyvale, CA, UNITED STATES
Cormier, Michel J.N., Mountain View, CA, UNITED STATES
Lin, WeiQi, Palo Alto, CA, UNITED STATES
PI US 20050153873 A1 20050714
AI US 2004-971441 A1 20041021 (10)
PRAI US 2004-535275P 20040109 (60)
DT Utility
FS APPLICATION
LN.CNT 1917
INCL INCLM: 514/002.000
INCLS: 604/500.000; 514/397.000; 514/171.000
NCL NCLM: 514/002.000
NCLS: 514/171.000; 514/397.000; 604/500.000
IC [7]
ICM A61K038-16
ICS A61K031-4172; A61M031-00
IPCI A61K0038-16 [ICM,7]; A61K0031-4172 [ICS,7]; A61K0031-4164
[I,C*,7]; A61M0031-00 [ICS,7]
IPCR A61K0031-4164 [I,C*]; A61K0031-4172 [I,A]; A61K0035-66 [I,C*];
A61K0035-74 [I,A]; A61K0035-76 [I,A]; A61K0038-04 [I,C*];
A61K0038-04 [I,A]; A61K0038-10 [I,C*]; A61K0038-11 [I,A];
A61K0038-16 [I,C*]; A61K0038-16 [I,A]; A61K0038-18 [I,C*];
A61K0038-18 [I,A]; A61K0038-19 [I,C*]; A61K0038-19 [I,A];
A61K0038-20 [I,C*]; A61K0038-20 [I,A]; A61K0038-21 [I,C*];
A61K0038-21 [I,A]; A61K0038-22 [I,C*]; A61K0038-22 [I,A];
A61K0038-23 [I,C*]; A61K0038-23 [I,A]; A61K0038-24 [I,C*];
A61K0038-24 [I,A]; A61K0038-25 [I,C*]; A61K0038-25 [I,A];
A61K0038-26 [I,C*]; A61K0038-26 [I,A]; A61K0038-27 [I,C*];
A61K0038-27 [I,A]; A61K0038-28 [I,C*]; A61K0038-28 [I,A];
A61K0038-29 [I,C*]; A61K0038-29 [I,A]; A61K0038-30 [I,C*];
A61K0038-30 [I,A]; A61K0038-31 [I,C*]; A61K0038-31 [I,A];
A61K0038-33 [I,C*]; A61K0038-33 [I,A]; A61K0038-34 [I,A];
A61K0038-35 [I,A]; A61K0038-43 [I,C*]; A61K0038-48 [I,A];
A61K0038-49 [I,A]; A61M0031-00 [I,C*]; A61M0031-00 [I,A];
A61M0037-00 [I,C*]; A61M0037-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 21 OF 41 USPATFULL on STN

Full Text

AN 2005:130676 USPATFULL
TI Ultrasound assisted transdermal vaccine delivery method and system
IN Cormier, Michel J.N., Mountain View, CA, UNITED STATES
Lin, WeiQi, Palo Alto, CA, UNITED STATES
Widera, Georg, Palo Alto, CA, UNITED STATES
PI US 20050112135 A1 20050526
AI US 2004-971338 A1 20041021 (10)
PRAI US 2003-524062P 20031121 (60)
DT Utility
FS APPLICATION
LN.CNT 2187
INCL INCLM: 424/185.100
INCLS: 604/500.000
NCL NCLM: 424/185.100
NCLS: 604/500.000
IC [7]
ICM A61K039-12
ICS A61M031-00
IPCI A61K0039-12 [ICM,7]; A61M0031-00 [ICS,7]
IPCR A61B0017-20 [I,C*]; A61B0017-20 [I,A]; A61K0039-00 [I,C*];
A61K0039-00 [I,A]; A61K0039-12 [I,C*]; A61K0039-12 [I,A];
A61K0039-29 [I,C*]; A61K0039-29 [I,A]; A61M0037-00 [I,C*];
A61M0037-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 22 OF 41 USPATFULL on STN

Full Text

AN 2005:75913 USPATFULL
TI Absorbable implants and methods for their use in hemostasis and in the
treatment of osseous defects
IN Kronenthal, Richard L., Fair Lawn, NJ, UNITED STATES
PI US 20050065214 A1 20050324
AI US 2004-941890 A1 20040916 (10)
PRAI US 2003-504978P 20030923 (60)
DT Utility
FS APPLICATION
LN.CNT 2741
INCL INCLM: 514/557.000
INCLS: 424/464.000
NCL NCLM: 514/557.000
NCLS: 424/464.000
IC [7]
ICM A61K009-20
ICS A61K031-19
IPCI A61K0009-20 [ICM,7]; A61K0031-19 [ICS,7]; A61K0031-185 [ICS,7,C*]
IPCR A61K0031-185 [I,C*]; A61K0031-19 [I,A]; A61L0024-00 [I,C*];
A61L0024-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 23 OF 41 USPATFULL on STN

Full Text

AN 2005:57631 USPATFULL
TI Method and device for enhancing transdermal agent flux
IN Wong, Patrick S.L., Burlingame, CA, UNITED STATES
Daddona, Peter, Menlo Park, CA, UNITED STATES
PI US 20050049549 A1 20050303
AI US 2004-911299 A1 20040803 (10)
PRAI US 2003-492610P 20030804 (60)
DT Utility
FS APPLICATION
LN.CNT 1208
INCL INCLM: 604/046.000
INCLS: 604/264.000
NCL NCLM: 604/046.000
NCLS: 604/264.000
IC [7]
ICM A61B017-20
ICS A61M025-00

IPCI A61B0017-20 [ICM,7]; A61M0025-00 [ICS,7]
IPCR A61B0010-00 [I,C*]; A61B0010-00 [I,A]; A61B0017-20 [I,C*];
A61B0017-20 [I,A]; A61M0037-00 [I,C*]; A61M0037-00 [I,A]

L17 ANSWER 24 OF 41 USPATFULL on STN

Full Text

AN 2005:56215 USPATFULL
TI Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
IN Rabinow, Barrett, Skokie, IL, UNITED STATES
White, Randy, Wodbury, MN, UNITED STATES
Sun, Chong-Son, Lake Forest, IL, UNITED STATES
Wong, Joseph Chung Tak, Gurnee, IL, UNITED STATES
Kipp, James E., Wauconda, IL, UNITED STATES
Doty, Mark J., Grayslake, IL, UNITED STATES
Rebbeck, Christine, Algonquin, IL, UNITED STATES
Papadopoulos, Pavlos George, Antioch, IL, UNITED STATES
PI US 20050048126 A1 20050303
AI US 2004-834541 A1 20040429 (10)
RLI Continuation-in-part of Ser. No. US 2002-270268, filed on 11 Oct 2002, PENDING Continuation-in-part of Ser. No. US 2002-246802, filed on 17 Sep 2002, PENDING Continuation-in-part of Ser. No. US 2001-35821, filed on 19 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2001-21692, filed on 12 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2001-953979, filed on 17 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2001-874637, filed on 5 Jun 2001, PENDING
PRAI US 2003-466354P 20030429 (60)
US 2000-258160P 20001222 (60)
DT Utility
FS APPLICATION
LN.CNT 1784
INCL INCLM: 424/489.000
INCLS: 514/254.070; 514/383.000
NCL NCLM: 424/489.000
NCLS: 514/254.070; 514/383.000
IC [7]
ICM A61K031-496
ICS A61K031-4196; A61K009-14
IPCI A61K0031-496 [ICM,7]; A61K0031-4196 [ICS,7]; A61K0009-14 [ICS,7]
IPCR A61K0009-10 [I,C*]; A61K0009-10 [I,A]; A61K0009-14 [I,C*];
A61K0009-14 [I,A]; A61K0009-16 [N,C*]; A61K0009-16 [N,A];
A61K0009-50 [I,C*]; A61K0009-50 [I,A]; A61K0009-51 [I,C*];
A61K0009-51 [I,A]; A61K0031-495 [I,C*]; A61K0031-495 [I,A];
A61K0031-496 [I,C*]; A61K0031-496 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 25 OF 41 USPATFULL on STN

Full Text

AN 2005:37001 USPATFULL
TI Method and device for enhancing transdermal agent flux
IN Wong, Patrick S.L., Burlingame, CA, UNITED STATES
Daddona, Peter, Menlo Park, CA, UNITED STATES
PI US 20050031676 A1 20050210
AI US 2004-910889 A1 20040803 (10)
PRAI US 2003-492610P 20030804 (60)
DT Utility
FS APPLICATION
LN.CNT 1545
INCL INCLM: 424/448.000
INCLS: 424/085.200; 514/012.000; 514/015.000; 604/500.000
NCL NCLM: 424/448.000
NCLS: 424/085.200; 514/012.000; 514/015.000; 604/500.000
IC [7]
ICM A61K038-19
ICS A61L015-16
IPCI A61K0038-19 [ICM,7]; A61L0015-16 [ICS,7]
IPCR A61B0010-00 [I,C*]; A61B0010-00 [I,A]; A61B0017-20 [I,C*];
A61B0017-20 [I,A]; A61M0037-00 [I,C*]; A61M0037-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 26 OF 41 USPATFULL on STN

Full Text

AN 2004:315117 USPATFULL
 TI Stabilised solid compositions of factor VII polypeptides
 IN Jensen, Michael Bech, Allerod, DENMARK
 Hansen, Birthe Lykkegaard, Vaerloose, DENMARK
 Kornfelt, Troels, Virum, DENMARK
 PI US 20040248793 A1 20041209
 AI US 2003-609780 A1 20030630 (10)
 RLI Continuation of Ser. No. WO 2003-DK419, filed on 20 Jun 2003, UNKNOWN
 PRAI DK 2002-963 20020621
 US 2002-394153P 20020703 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1869
 INCL INCLM: 514/012.000
 INCLS: 514/053.000
 NCL NCLM: 514/012.000
 NCLS: 514/053.000
 IC [7]
 ICM A61K038-37
 ICS A61K031-7012
 IPCI A61K0038-37 [ICM,7]; A61K0038-36 [ICM,7,C*]; A61K0031-7012
 [ICS,7]
 IPCR A61K0038-43 [I,C*]; A61K0038-48 [I,A]; A61K0047-02 [I,C*];
 A61K0047-02 [I,A]; A61K0047-16 [I,C*]; A61K0047-18 [I,A];
 A61K0047-26 [I,C*]; A61K0047-26 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 27 OF 41 USPATFULL on STN

Full Text

AN 2004:220917 USPATFULL
 TI Sustained release matrix systems for highly soluble drugs
 IN Baichwal, Anand R., Wappingers Falls, NY, UNITED STATES
 McCall, Troy W., Germantown, TN, UNITED STATES
 Liu, Lirong, Washington Township, NJ, UNITED STATES
 Labudzinski, Steve, Poughkeepsie, NY, UNITED STATES
 PA Penwest Pharmaceuticals Co., Patterson, NY, UNITED STATES (U.S.
 corporation)
 PI US 20040170684 A1 20040902
 AI US 2003-740213 A1 20031218 (10)
 RLI Continuation of Ser. No. US 2000-676376, filed on 29 Sep 2000, PENDING
 PRAI US 1999-157200P 19990930 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2322
 INCL INCLM: 424/468.000
 NCL NCLM: 424/468.000
 IC [7]
 ICM A61K009-22
 IPCI A61K0009-22 [ICM,7]
 IPCR A61K0009-20 [I,C*]; A61K0009-20 [I,A]; A61K0009-22 [I,C*];
 A61K0009-22 [I,A]; A61K0009-28 [I,C*]; A61K0009-28 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 28 OF 41 USPATFULL on STN

Full Text

AN 2004:209343 USPATFULL
 TI PSMA formulations and uses thereof
 IN Maddon, Paul J., Scarsdale, NY, UNITED STATES
 Donovan, Gerald P., New York, NY, UNITED STATES
 Olson, William C., Ossining, NY, UNITED STATES
 Schulke, Norbert, New City, NY, UNITED STATES
 Gardner, Jason, Ardsley, NY, UNITED STATES
 Ma, Dangshe, Millwood, NY, UNITED STATES
 PI US 20040161776 A1 20040819
 AI US 2003-695667 A1 20031027 (10)
 RLI Continuation-in-part of Ser. No. US 2003-395894, filed on 21 Mar 2003,
 PENDING Continuation-in-part of Ser. No. WO 2002-US33944, filed on 23
 Oct 2002, PENDING
 PRAI US 2001-335215P 20011023 (60)
 US 2002-362747P 20020307 (60)
 US 2002-412618P 20020920 (60)
 DT Utility

FS APPLICATION
LN.CNT 7924
INCL INCLM: 435/006.000
INCLS: 435/007.230; 435/069.100; 435/320.100; 435/325.000; 530/350.000;
536/023.500
NCL NCLM: 435/006.000
NCLS: 435/007.230; 435/069.100; 435/320.100; 435/325.000; 530/350.000;
536/023.500
IC [7]
ICM C12Q001-68
ICS G01N033-574; C07H021-04; C07K014-705
IPCI C12Q0001-68 [ICM,7]; G01N0033-574 [ICS,7]; C07H0021-04 [ICS,7];
C07H0021-00 [ICS,7,C*]; C07K0014-705 [ICS,7]; C07K0014-435
[ICS,7,C*]
IPCR A61K0047-48 [I,C*]; A61K0047-48 [I,A]; A61K0051-02 [I,C*];
A61K0051-10 [I,A]; C07K0016-18 [I,C*]; C07K0016-30 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 29 OF 41 USPATFULL on STN

Full Text

AN 2004:199408 USPATFULL
TI Glucose sensor
IN Yugawa, Keiko, Nara, JAPAN
Yoshioka, Toshihiko, Hirakata, JAPAN
Nankai, Shiro, Hirakata, JAPAN
Iwata, Junko, Ehime, JAPAN
Miyazaki, Shoji, Matsuyama, JAPAN
Baba, Hideyuki, Matsuyama, JAPAN
Takeshima, Seiji, Tsuruga, JAPAN
PA Matsushita Electric Industrial Co., Ltd., Osaka, JAPAN (non-U.S.
corporation)
Toyobo Co., Ltd., Osaka, JAPAN (non-U.S. corporation)
PI US 6773564 B1 20040810
AI US 1999-406832 19990928 (9)
PRAI JP 1998-276153 19980929
JP 1999-212703 19990727
DT Utility
FS GRANTED
LN.CNT 1211
INCL INCLM: 204/403.140
INCLS: 435/014.000; 435/190.000
NCL NCLM: 204/403.140
NCLS: 435/014.000; 435/190.000
IC [7]
ICM G01N027-327
ICS C12Q001-54; C12N009-04
IPCI G01N0027-327 [ICM,7]; C12Q0001-54 [ICS,7]; C12N0009-04 [ICS,7]
IPCR G01N0027-327 [I,C*]; G01N0027-327 [I,A]; C12Q0001-00 [I,C*];
C12Q0001-00 [I,A]; G01N0027-416 [I,C*]; G01N0027-416 [I,A];
G01N0033-487 [I,C*]; G01N0033-487 [I,A]
EXF 204/403; 204/403.01; 204/403.04; 204/403.09; 204/403.1; 204/403.11;
204/403.12; 204/403.14; 435/14; 435/189; 435/190; 205/777.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 30 OF 41 USPATFULL on STN

Full Text

AN 2004:88942 USPATFULL
TI Injectable 2, 6-diisopropylphenol-containing anesthetic composition and
methods
IN Jee, Ung-Kil, Seoul, KOREA, REPUBLIC OF
PA Centurion Inc. (non-U.S. corporation)
PI US 20040067919 A1 20040408
AI US 2003-615763 A1 20030708 (10)
PRAI KR 2002-61260 20021008
DT Utility
FS APPLICATION
LN.CNT 809
INCL INCLM: 514/171.000
INCLS: 514/731.000
NCL NCLM: 514/171.000
NCLS: 514/731.000
IC [7]

ICM A61K031-05
 ICS A61K031-56
 IPCI A61K0031-05 [ICM,7]; A61K0031-045 [ICM,7,C*]; A61K0031-56 [ICS,7]
 IPCR A61K0009-10 [I,C*]; A61K0009-10 [I,A]; A61K0009-107 [I,C*];
 A61K0009-107 [I,A]; A61K0031-045 [I,C*]; A61K0031-05 [I,A];
 A61K0031-56 [I,C*]; A61K0031-56 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 31 OF 41 USPATFULL on STN

Full Text

AN 2004:44253 USPATFULL
 TI SINICALIDE FORMULATIONS
 IN Metcalfe, Edmund C., Hillsborough, NJ, UNITED STATES
 Monteferrante, Jo Anna, Raritan Township, NJ, UNITED STATES
 Newborn, Margaret, Hamilton Township, NJ, UNITED STATES
 Ropiak, Irene, Lawrenceville, NJ, UNITED STATES
 Schramm, Ernst, North Brunswick, NJ, UNITED STATES
 White, Gregory W., Monmouth Junction, NJ, UNITED STATES
 Zodda, Julius P., Mercerville, NJ, UNITED STATES

PI US 20040033243 A1 20040219
 US 6803046 B2 20041012
 AI US 2002-222540 A1 20020816 (10)

DT Utility
 FS APPLICATION

LN.CNT 2183

INCL INCLM: 424/400.000

INCLS: 514/016.000

NCL NCLM: 424/400.000

NCLS: 514/018.000; 514/019.000; 514/951.000; 514/016.000

IC [7]

ICM A61K038-08
 IPCI A61K0038-08 [ICM,7]
 IPCI-2 A61K0009-00 [ICM,7]
 IPCR A61K0038-22 [I,C*]; A61K0038-22 [I,A]; A61K0047-00 [I,C*];
 A61K0047-00 [I,A]; A61K0049-00 [I,C*]; A61K0049-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 32 OF 41 USPATFULL on STN

Full Text

AN 2004:13396 USPATFULL
 TI Stabilised solid compositions of modified factor VII
 IN Nedergaard, Hanne, Kobenhavn, DENMARK
 Hansen, Lars Lindgaard, Gadstrup, DENMARK
 Klausen, Niels Kristian, Gentofte, DENMARK
 Kornfelt, Troels, Virum, DENMARK
 Flink, James M., Klampenborg, DENMARK

PI US 20040009918 A1 20040115
 AI US 2003-427395 A1 20030501 (10)

PRAI DK 2002-677 20020503
 US 2002-380543P 20020513 (60)

DT Utility
 FS APPLICATION

LN.CNT 1666

INCL INCLM: 514/012.000

INCLS: 514/053.000; 514/058.000

NCL NCLM: 514/012.000

NCLS: 514/053.000; 514/058.000

IC [7]

ICM A61K038-37
 ICS A61K031-724; A61K031-7012
 IPCI A61K0038-37 [ICM,7]; A61K0038-36 [ICM,7,C*]; A61K0031-724
 [ICS,7]; A61K0031-716 [ICS,7,C*]; A61K0031-7012 [ICS,7]
 IPCR A61K0047-16 [I,C*]; A61K0047-18 [I,A]; A61K0047-26 [I,C*];
 A61K0047-26 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 33 OF 41 USPATFULL on STN

Full Text

AN 2003:245042 USPATFULL
 TI Underfill encapsulant for wafer packaging and method for its application
 IN Tong, Quinn K., Belle Mead, NJ, UNITED STATES
 Xiao, Yue, Belle Mead, NJ, UNITED STATES

Ma, Bodan, Racine, WI, UNITED STATES
Hong, Sun Hee, Hillsborough, NJ, UNITED STATES
PI US 20030171456 A1 20030911
US 7037399 B2 20060502
AI US 2002-84869 A1 20020301 (10)
DT Utility
FS APPLICATION
LN.CNT 648
INCL INCLM: 523/404.000
NCL NCLM: 156/256.000; 523/404.000
NCLS: 156/330.000; 257/793.000; 257/E21.503; 257/E23.119; 428/620.000;
523/466.000; 528/094.000; 528/103.000; 528/405.000; 528/407.000;
528/418.000; 528/419.000
IC [7]
ICM C08K003-20
IPCI C08K0003-20 [ICM,7]; C08K0003-00 [ICM,7,C*]
IPCI-2 B32B0031-12 [I,A]
IPCR B32B0037-00 [I,C*]; C08G0065-00 [I,C*]; C08G0065-04 [I,A];
C08G0059-00 [I,C*]; C08G0059-50 [I,A]; C08G0059-58 [I,A];
C08G0059-68 [I,A]; H01L0021-02 [I,C*]; H01L0021-56 [I,A];
H01L0023-28 [I,C*]; H01L0023-29 [I,A]; H01L0023-31 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 34 OF 41 USPATFULL on STN

Full Text

AN 2003:236399 USPATFULL
TI B-stageable underfill encapsulant and method for its application
IN Tong, Quinn K., Belle Mead, NJ, UNITED STATES
Xiao, Yue, Belle Mead, NJ, UNITED STATES
Ma, Bodan, Racine, WI, UNITED STATES
Dutt, Gyanendra, Edison, NJ, UNITED STATES
PI US 20030164555 A1 20030904
AI US 2002-84873 A1 20020301 (10)
DT Utility
FS APPLICATION
LN.CNT 810
INCL INCLM: 257/787.000
INCLS: 257/788.000; 257/793.000; 438/127.000; 438/113.000; 438/114.000
NCL NCLM: 257/787.000
NCLS: 257/788.000; 257/793.000; 257/E21.503; 257/E23.119; 438/113.000;
438/114.000; 438/127.000
IC [7]
ICM H01L021-44
ICS H01L021-56
IPCI H01L0021-44 [ICM,7]; H01L0021-56 [ICS,7]; H01L0021-02 [ICS,7,C*]
IPCR C08K0003-00 [I,C*]; C08K0003-00 [I,A]; C08G0059-00 [I,C*];
C08G0059-20 [I,A]; C08G0059-50 [I,A]; C08G0059-62 [I,A];
C08G0059-68 [I,A]; C08K0005-00 [I,C*]; C08K0005-00 [I,A];
C08L0063-00 [I,C*]; C08L0063-00 [I,A]; H01L0021-02 [I,C*];
H01L0021-56 [I,A]; H01L0023-28 [I,C*]; H01L0023-29 [I,A];
H01L0023-31 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 35 OF 41 USPATFULL on STN

Full Text

AN 2003:232710 USPATFULL
TI No flow underfill composition
IN Xiao, Yue, Belle Mead, NJ, UNITED STATES
Tong, Quinn K., Belle Mead, NJ, UNITED STATES
Morganelli, Paul, Upton, MA, UNITED STATES
Shah, Jayesh, Plaistow, NH, UNITED STATES
PI US 20030162911 A1 20030828
AI US 2002-62902 A1 20020131 (10)
DT Utility
FS APPLICATION
LN.CNT 521
INCL INCLM: 525/533.000
NCL NCLM: 525/533.000
NCLS: 257/E21.503; 257/E23.119
IC [7]
ICM C08G059-14
IPCI C08G0059-14 [ICM,7]; C08G0059-00 [ICM,7,C*]

IPCR C09K0003-10 [I,C*]; C09K0003-10 [I,A]; C08G0059-00 [I,C*];
C08G0059-42 [I,A]; C08G0059-62 [I,A]; C08L0063-00 [I,C*];
C08L0063-02 [I,A]; H01L0021-02 [I,C*]; H01L0021-56 [I,A];
H01L0023-28 [I,C*]; H01L0023-29 [I,A]; H01L0023-31 [I,A];
H05K0003-28 [I,C*]; H05K0003-28 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 36 OF 41 USPATFULL on STN

Full Text

AN 2003:194950 USPATFULL
TI Foaming composition based on silica and on cationic polymer
IN Sebillotte-Arnaud, Laurence, L'Hay les Roses, FRANCE
Bordeaux, Dominique, Longpont sur Orge, FRANCE
PA L'OREAL, Paris, FRANCE (non-U.S. corporation)
PI US 20030134761 A1 20030717
US 6894012 B2 20050517
AI US 2002-199177 A1 20020722 (10)
PRAI FR 2001-9767 20010720
DT Utility
FS APPLICATION
LN.CNT 1498
INCL INCLM: 510/130.000
INCLS: 510/421.000; 510/504.000; 510/475.000
NCL NCLM: 510/136.000; 510/130.000
NCLS: 510/119.000; 510/128.000; 510/130.000; 510/131.000; 510/421.000;
510/475.000; 510/486.000; 510/504.000; 510/511.000
IC [7]
ICM A61K007-50
IPCI A61K0007-50 [ICM,7]
IPCI-2 C11D0001-72 [ICM,7]; C11D0003-08 [ICS,7]; C11D0003-37 [ICS,7]
IPCR A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-19 [I,C*];
A61K0008-19 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A];
A61K0008-30 [I,C*]; A61K0008-30 [I,A]; A61K0008-34 [I,A];
A61K0008-36 [I,A]; A61K0008-365 [I,A]; A61K0008-368 [I,A];
A61K0008-37 [I,A]; A61K0008-39 [I,A]; A61K0008-40 [I,A];
A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-55 [I,A];
A61K0008-60 [I,A]; A61K0008-66 [I,A]; A61K0008-67 [I,A];
A61K0008-72 [I,C*]; A61K0008-72 [I,A]; A61K0008-73 [I,A];
A61K0008-81 [I,A]; A61K0008-84 [I,A]; A61K0008-86 [I,A];
A61K0008-88 [I,A]; A61K0008-92 [I,C*]; A61K0008-92 [I,A];
A61K0008-96 [I,C*]; A61K0008-96 [I,A]; A61Q0001-02 [I,C*];
A61Q0001-02 [I,A]; A61Q0001-14 [I,C*]; A61Q0001-14 [I,A];
A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0019-10 [I,C*];
A61Q0019-10 [I,A]; C11D0001-02 [N,C*]; C11D0001-34 [N,A];
C11D0001-66 [N,C*]; C11D0001-66 [N,A]; C11D0001-74 [N,C*];
C11D0001-74 [N,A]; C11D0003-12 [I,C*]; C11D0003-12 [I,A];
C11D0003-20 [I,C*]; C11D0003-20 [I,A]; C11D0003-22 [I,C*];
C11D0003-22 [I,A]; C11D0003-37 [I,C*]; C11D0003-37 [I,A];
C11D0003-38 [I,C*]; C11D0003-38 [I,A]; C11D0003-386 [I,A];
C11D0003-48 [I,C*]; C11D0003-48 [I,A]; C11D0017-00 [I,C*];
C11D0017-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 37 OF 41 USPATFULL on STN

Full Text

AN 2001:33254 USPATFULL
TI Particles, especially microparticles or nanoparticles, of crosslinked
monosaccharides and oligosaccharides, processes for their preparation
and cosmetic, pharmaceutical or food compositions in which they are
present
IN Perrier, Eric, Quartier St Martin, 38138 les Cotes d'Arey, France
Rey-Goutenoire, Sylvie, les Varines, 69420 les Haies, France
Buffevant, Chantal, les Carres, 69390 Millery, France
Levy, Marie-Christine, 18 Ter rue Houzeau-Muiron, 51100 Reims, France
Pariot, Nadine, 14, rue Saint Leonard, 51100 Reims, France
Edwards, Florence, 5-7, rue de la Belle aumone, 02160 Longueval, France
Andry, Marie-Christine, 221, avenue du General Leclerc, 51530 Dizy,
France
PI US 6197757 B1 20010306
AI US 1999-350131 19990709 (9)
PRAI FR 1998-889 19980709
DT Utility

FS Granted
LN.CNT 2290
INCL INCLM: 514/053.000
INCLS: 514/023.000; 514/054.000; 536/001.110; 536/103.000; 536/123.130;
536/124.000
NCL NCLM: 514/053.000
NCLS: 514/023.000; 514/054.000; 536/001.110; 536/103.000; 536/123.130;
536/124.000; 977/773.000; 977/775.000; 977/795.000; 977/926.000
IC [7]
ICM A61K031-70
ICS C07H001-00; C07H003-00
IPCI A61K0031-70 [ICM,7]; C07H0001-00 [ICS,7]; C07H0003-00 [ICS,7]
IPCR C08B0037-00 [I,C*]; C08B0037-00 [I,A]; A61K0008-11 [I,C*];
A61K0008-11 [I,A]; A61K0008-30 [I,C*]; A61K0008-35 [I,A];
A61K0008-64 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A];
A61K0009-51 [I,C*]; A61K0009-51 [I,A]; A61K0009-52 [I,C*];
A61K0009-52 [I,A]; A61K0009-62 [I,A]; A61P0031-00 [I,C*];
A61P0031-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A];
A61Q0001-02 [I,C*]; A61Q0001-06 [I,A]; A61Q0001-10 [I,A];
A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0019-10 [I,C*];
A61Q0019-10 [I,A]; B01J0013-02 [I,C*]; B01J0013-02 [I,A];
C07H0003-00 [I,C*]; C07H0003-00 [I,A]
EXF 536/1.11; 536/103; 536/123.13; 536/124; 514/23; 514/53; 514/54
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 38 OF 41 USPATFULL on STN

Full Text

AN 87:18621 USPATFULL
TI Method to make effervescent calcium tablets and calcium tablets produced
thereby
IN Alexander, Thomas A., South Bend, IN, United States
Peterson, Donald L., Elkhart, IN, United States
PA Miles Laboratories, Inc., Elkhart, IN, United States (U.S. corporation)
PI US 4650669 19870317
AI US 1985-760685 19850730 (6)
DT Utility
FS Granted
LN.CNT 530
INCL INCLM: 424/044.000
INCLS: 424/466.000; 424/156.000
NCL NCLM: 424/044.000
NCLS: 424/466.000; 424/687.000; 424/700.000
IC [4]
ICM A61K009-46
ICS A61K009-62; A61K033-10
IPCI A61K0009-46 [ICM,4]; A61K0009-62 [ICS,4]; A61K0009-52 [ICS,4,C*];
A61K0033-10 [ICS,4]; A61K0033-06 [ICS,4,C*]
IPCR A61K0009-46 [I,C*]; A61K0009-46 [I,A]; A61K0033-06 [I,C*];
A61K0033-10 [I,A]
EXF 424/44; 424/156; 424/35
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 39 OF 41 USPAT2 on STN

Full Text

AN 2004:44253 USPAT2
TI Sincalide formulations
IN Metcalfe, Edmund C., Hillsborough, NJ, United States
Monteferrante, Jo Anna, Raritan Township, NJ, United States
Newborn, Margaret, Hamilton Township, NJ, United States
Ropiak, Irene, Lawrenceville, NJ, United States
Schramm, Ernst, North Brunswick, NJ, United States
White, Gregory W., Monmouth Junction, NJ, United States
Zodda, Julius P., Mercerville, NJ, United States
PA Bracco International B.V., Amsterdam, NETHERLANDS (non-U.S. corporation)
PI US 6803046 B2 20041012
AI US 2002-222540 20020816 (10)
DT Utility
FS GRANTED
LN.CNT 2058
INCL INCLM: 424/400.000
INCLS: 514/001.650; 514/018.000; 514/019.000; 514/951.000
NCL NCLM: 424/400.000

NCLS: 514/018.000; 514/019.000; 514/951.000; 514/016.000
 IC [7]
 ICM A61K009-00
 IPCI A61K0038-08 [ICM,7]
 IPCI-2 A61K0009-00 [ICM,7]
 IPCR A61K0038-22 [I,C*]; A61K0038-22 [I,A]; A61K0047-00 [I,C*];
 A61K0047-00 [I,A]; A61K0049-00 [I,C*]; A61K0049-00 [I,A]
 EXF 424/400; 514/18; 514/19; 514/1.65; 514/951
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 40 OF 41 USPAT2 on STN

Full Text

AN 2003:245042 USPAT2
 TI Underfill encapsulant for wafer packaging and method for its application
 IN Tong, Quinn K., Belle Mead, NJ, UNITED STATES
 Xiao, Yue, Belle Mead, NJ, UNITED STATES
 Ma, Bodan, Racine, WI, UNITED STATES
 Hong, Sun Hee, Hillsborough, NJ, UNITED STATES
 PA National Starch and Chemical Investment Holding Corporation, New Castle,
 DE, UNITED STATES (U.S. corporation)
 PI US 7037399 B2 20060502
 AI US 2002-84869 20020301 (10)
 DT Utility
 FS GRANTED
 LN.CNT 622
 INCL INCLM: 156/256.000
 INCLS: 156/330.000; 257/793.000; 428/620.000; 523/466.000; 528/094.000;
 528/103.000; 528/405.000; 528/407.000; 528/418.000; 528/419.000
 NCL NCLM: 156/256.000; 523/404.000
 NCLS: 156/330.000; 257/793.000; 257/E21.503; 257/E23.119; 428/620.000;
 523/466.000; 528/094.000; 528/103.000; 528/405.000; 528/407.000;
 528/418.000; 528/419.000
 IC IPCI C08K0003-20 [ICM,7]; C08K0003-00 [ICM,7,C*]
 IPCI-2 B32B0031-12 [I,A]
 IPCR B32B0037-00 [I,C*]; C08G0065-00 [I,C*]; C08G0065-04 [I,A];
 C08G0059-00 [I,C*]; C08G0059-50 [I,A]; C08G0059-58 [I,A];
 C08G0059-68 [I,A]; H01L0021-02 [I,C*]; H01L0021-56 [I,A];
 H01L0023-28 [I,C*]; H01L0023-29 [I,A]; H01L0023-31 [I,A]
 EXF 257/793; 428/620; 438/113; 438/114; 438/118; 438/127; 523/466; 528/94;
 528/103; 528/103.5; 528/405; 528/407; 528/418; 528/419; 156/256; 156/330
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 41 OF 41 USPAT2 on STN

Full Text

AN 2003:194950 USPAT2
 TI Foaming composition based on silica and on cationic polymer
 IN Sebillotte-Arnaud, Laurence, L'Hay les Roses, FRANCE
 Bordeaux, Dominique, Longpont sur Orge, FRANCE
 PA L'Oreal, Paris, FRANCE (non-U.S. corporation)
 PI US 6894012 B2 20050517
 AI US 2002-199177 20020722 (10)
 PRAI FR 2001-9767 20010720
 DT Utility
 FS GRANTED
 LN.CNT 1437
 INCL INCLM: 510/136.000
 INCLS: 510/119.000; 510/128.000; 510/130.000; 510/131.000; 510/421.000;
 510/475.000; 510/486.000; 510/504.000; 510/511.000
 NCL NCLM: 510/136.000; 510/130.000
 NCLS: 510/119.000; 510/128.000; 510/130.000; 510/131.000; 510/421.000;
 510/475.000; 510/486.000; 510/504.000; 510/511.000
 IC [7]
 ICM C11D001-72
 ICS C11D003-08; C11D003-37
 IPCI A61K0007-50 [ICM,7]
 IPCI-2 C11D0001-72 [ICM,7]; C11D0003-08 [ICS,7]; C11D0003-37 [ICS,7]
 IPCR A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A61K0008-19 [I,C*];
 A61K0008-19 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A];
 A61K0008-30 [I,C*]; A61K0008-30 [I,A]; A61K0008-34 [I,A];
 A61K0008-36 [I,A]; A61K0008-365 [I,A]; A61K0008-368 [I,A];
 A61K0008-37 [I,A]; A61K0008-39 [I,A]; A61K0008-40 [I,A];
 A61K0008-42 [I,A]; A61K0008-44 [I,A]; A61K0008-55 [I,A];

```

A61K0008-60 [I,A]; A61K0008-66 [I,A]; A61K0008-67 [I,A];
A61K0008-72 [I,C*]; A61K0008-72 [I,A]; A61K0008-73 [I,A];
A61K0008-81 [I,A]; A61K0008-84 [I,A]; A61K0008-86 [I,A];
A61K0008-88 [I,A]; A61K0008-92 [I,C*]; A61K0008-92 [I,A];
A61K0008-96 [I,C*]; A61K0008-96 [I,A]; A61Q0001-02 [I,C*];
A61Q0001-02 [I,A]; A61Q0001-14 [I,C*]; A61Q0001-14 [I,A];
A61Q0005-02 [I,C*]; A61Q0005-02 [I,A]; A61Q0019-10 [I,C*];
A61Q0019-10 [I,A]; C11D0001-02 [N,C*]; C11D0001-34 [N,A];
C11D0001-66 [N,C*]; C11D0001-66 [N,A]; C11D0001-74 [N,C*];
C11D0001-74 [N,A]; C11D0003-12 [I,C*]; C11D0003-12 [I,A];
C11D0003-20 [I,C*]; C11D0003-20 [I,A]; C11D0003-22 [I,C*];
C11D0003-22 [I,A]; C11D0003-37 [I,C*]; C11D0003-37 [I,A];
C11D0003-38 [I,C*]; C11D0003-38 [I,A]; C11D0003-386 [I,A];
C11D0003-48 [I,C*]; C11D0003-48 [I,A]; C11D0017-00 [I,C*];
C11D0017-00 [I,A]
EXF 510/119; 510/128; 510/136; 510/130; 510/131; 510/421; 510/475; 510/486;
510/504; 510/511
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```

=> d l17 an ti pa so pi ab kwic 37 41

'SO' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):end

=> d his

(FILE 'HOME' ENTERED AT 20:29:26 ON 28 OCT 2008)

FILE 'MEDLINE' ENTERED AT 20:30:04 ON 28 OCT 2008

```

L1 10476 S (DISACCHARIDE OR TREHALOSE OR CELLOBIOSE)
L2 4865 S (DIACID OR DI-ACID OR SUCCINIC ACID OR ADIPIC ACID OR GLUTARI
L3 23 S L1 AND L2

```

FILE 'CA' ENTERED AT 20:32:50 ON 28 OCT 2008

```

L4 31173 S (DISACCHARIDE OR TREHALOSE OR CELLOBIOSE)/AB,BI
L5 99646 S (DIACID OR DI-ACID OR SUCCINIC ACID OR ADIPIC ACID OR GLUTARI
L6 480 S L4 AND L5
L7 201665 S (SURFACTANT)/AB,BI
L8 11 S L6 AND L7

```

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 20:36:21 ON 28 OCT 2008

```

L9 4035 S (DISACCHARIDE OR TREHALOSE OR CELLOBIOSE)/CLM
L10 143560 S (DIACID OR DI-ACID OR SUCCINIC ACID OR ADIPIC ACID OR GLUTARI
L11 18508 S (DIACID OR DI-ACID OR SUCCINIC ACID OR ADIPIC ACID OR GLUTARI
L12 31389 S (DISACCHARIDE OR TREHALOSE OR CELLOBIOSE)
L13 124 S L9 AND L11
L14 5250 S L10 AND L12
L15 197387 S (SURFACTANT)
L16 52521 S (SURFACTANT)/CLM
L17 41 S L13 AND L16
L18 2455 S L14 AND L15

```

=> d l17 an ti pa so pi ab kwic 37 41

'SO' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):end

=> d l17 an ti pa pi ab kwic 37 41

L17 ANSWER 37 OF 41 USPATFULL on STN

Full Text

AN 2001:33254 USPATFULL

TI Particles, especially microparticles or nanoparticles, of crosslinked monosaccharides and oligosaccharides, processes for their preparation and cosmetic, pharmaceutical or food compositions in which they are

present

PI US 6197757 B1 20010306

AB Particles comprising an outer wall formed of one or more saccharide components selected from the group consisting of monosaccharides and oligosaccharides crosslinked by interfacial crosslinking in emulsion, preferably at room temperature, with a polyfunctional acylating crosslinking agent to produce ester linkages between the acylatable hydroxyl group(s) of the primary alcohol(s) of the saccharide component and the acyl groups of the polyfunctional acylating agent. These particles can be used for the manufacture of cosmetic, pharmaceutical and food compositions.

CLM What is claimed is:

. . . 1, wherein said interfacial crosslinking in emulsion is performed at room temperature and said polyfunctional acylating crosslinking agent is a **diacid** halide.

CLM What is claimed is:

7. The particle of claim 1, wherein the oligosaccharide is selected from the group consisting of sucrose, lactose, maltose, **cellobiose**, **trehalose**, melibiose, raffinose, a dextrin, a product of the partial hydrolysis of starch, a polyol derived from an oligosaccharide, lactitol, maltitol. . . .

CLM What is claimed is:

. . . agent, said saccharide component being selected from the group consisting of: a β -Cyclodextrin, a mixture of dextrans commercially available, Raffinose, **Cellobiose**, Sucrose, Maltose, Lactose, **Trehalose**, Dihydroxyacetone (DHA), D-Fructose, Sorbose, D-Ribose, D-Deoxyribose, D-Xylose, Paranitrophenyl beta-D-xyloside, D-Arabinose, D-Glucose, D-Mannose, D-Galactose, Xylitol, Erythritol, Arabitol, Sorbitol, Mannitol, Dulcitol (galactitol),. . . .

CLM What is claimed is:

. . . composition, said saccharide component being selected from the group consisting of a β -Cyclodextrin, a mixture of dextrans commercially available, Raffinose, **Cellobiose**, Sucrose, Maltose, Lactose, **Trehalose**, Dihydroxyacetone (DHA), D-Fructose, Sorbose, D-Ribose, D-Deoxyribose, D-Xylose, Paranitrophenyl beta-D-xyloside, D-Arabinose, D-Glucose, D-Mannose, D-Galactose, Xylitol, Erythritol, Arabitol, Sorbitol, Mannitol, Dulcitol (galactitol),. . . .

CLM What is claimed is:

. . . said saccharide component is dissolved; b) the preparation of a hydrophobic phase essentially immiscible with water and optionally containing a **surfactant**; c) the dispersion of the aqueous phase in the hydrophobic phase by agitation so as to form an emulsion of. . . .

CLM What is claimed is:

. . . 55. The process of claim 45, wherein the polyfunctional acylating crosslinking agent is selected from the group consisting of a **diacid** dihalide and from a **diacid** anhydride.

CLM What is claimed is:

56. The process of claim 55, wherein said **diacid** dihalide is selected from the group consisting of phthaloyl dihalide, terephthaloyl dihalide, sebacoyl dihalide, glutaryl dihalide, adipoyl dihalide and succinyl dihalide; and said **diacid** anhydride is an anhydride having as **diacid** moiety the **diacid** moiety of the **diacid** dihalide.

L17 ANSWER 41 OF 41 USPAT2 on STN

Full Text

AN 2003:194950 USPAT2

TI Foaming composition based on silica and on cationic polymer

PA L'Oreal, Paris, FRANCE (non-U.S. corporation)

PI US 6894012 B2 20050517

AB The present application relates to a cleansing composition comprising, in a physiologically acceptable aqueous medium, (1) at least one foaming surfactant, (2) at least 1% by weight of at least one silica with respect to the total weight of the composition, (3) at least one oxyalkylated compound and (4) at least one polymer chosen from cationic polymers and amphoteric polymers.

The composition obtained has the consistency of a gel and gives a lather of very good quality. It can be used in particular in the cosmetic or dermatological field, as products for cleansing or removing make-up from

the skin, eyes, scalp and/or hair, and/or to disinfect the skin and/or the scalp.

CLM What is claimed is:

1. A physiologically acceptable composition comprising, water and: (1) at least one foaming **surfactant**, (2) at least 1% by weight of at least one silica, with respect to the total weight of the composition, .

CLM What is claimed is:

14. The composition according to claim 1, wherein the foaming **surfactant** is selected from the group consisting of nonionic surfactants, anionic surfactants, amphoteric and zwitterionic surfactants, and mixtures thereof.

CLM What is claimed is:

15. The composition according to claim 1, wherein the amount of foaming **surfactant** is present in an amount of from 2 to 50% by weight of active material with respect to the total. . .

CLM What is claimed is:

16. The composition according to claim 1, comprising a foaming **surfactant** selected from the group consisting of alkylpolyglucosides, maltose esters, polyglycerolated fatty alcohols, glucamine derivatives, carboxylates, amino acid derivatives, alkyl sulphates, . . .

CLM What is claimed is:

17. The composition according to claim 1, comprising a foaming **surfactant** selected from the group consisting of decylglucoside, caprylyl/caprylglucoside, laurylglucoside, cocoglucoside, lauryl monophosphate, the potassium salt of dodecyl phosphate, the mixture. .

CLM What is claimed is:

. . . vitamin B5, vitamin E, vitamin K1, β -carotene, and their derivatives; DHEA and 7 α -hydroxy-DHEA; benzoyl peroxide, salicylic acid, triclosan, triclocarban or **azelaic acid**; glycerol, hyaluronic acid, pyrrolidonecarboxylic acid and its salts, serine, xylitol, **trehalose**, ectoin, ceramides or urea; glycolic acid, citric acid, lactic acid, salicylic acid and its derivatives; coenzyme Q10; 18- β -glycyrrhetic acid, ursolic. . .

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

69.75

181.98

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-1.50

STN INTERNATIONAL LOGOFF AT 20:44:49 ON 28 OCT 2008